Revision as of 19:58, 28 March 2019

Page editor		Section editor
	Rozina Chowdhery, MD University of Illinois at Chicago Chicago, IL		Neeta K. Venepalli, MD, MBA University of Illinois at Chicago Chicago, IL

49 regimens on this page 82 variants on this page

Guidelines

ASCO

2018: Sohal et al. Metastatic pancreatic cancer: ASCO Clinical Practice Guideline update PubMed
2017: Khorana et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline update PubMed

Older

2016: Sohal et al. Metastatic pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline
2016: Balaban et al. Locally advanced, unresectable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline PubMed

ESMO

2017: eUpdate – Cancer of the Pancreas Treatment Recommendations
2015: Ducreux et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2015) PubMed

NCCN

NCCN Guidelines - Pancreatic Adenocarcinoma

Adjuvant therapy

Capecitabine & Gemcitabine

back to top

GemCap: Gemcitabine & Capecitabine

Regimen

Study	Evidence	Comparator	Efficacy
Neoptolemos et al. 2017 (ESPAC-4)	Phase III (E)	Gemcitabine	Seems to have superior OS

Treatment starts within 12 weeks of surgery.

Preceding treatment

Surgery

Chemotherapy

Capecitabine (Xeloda) 1660 mg/m²/day PO on days 1 to 21 (frequency of dosing not specified)
Gemcitabine (Gemzar) 1000 mg/m² IV once per week on weeks 1 to 3

28-day cycle for 6 cycles

References

ESPAC-4: Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Hackert T, Jackson R, Büchler MW; European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017 Mar 11;389(10073):1011-1024. Epub 2017 Jan 25. link to original article contains protocol PubMed

Fluorouracil & Folinic acid

back to top

Regimen

Study	Evidence	Comparator	Efficacy
Neoptolemos et al. 2001 (ESPAC-1)	Phase III (E)	1. 5-FU/5-FU & RT 2. 5-FU & RT, then 5-FU & Leucovorin	Seems to have superior OS (*)
Neoptolemos et al. 2001 (ESPAC-1)	Phase III (E)	3. Observation	Superior OS (*)
Neoptolemos et al. 2010 (ESPAC-3 version 2)	Phase III (C)	Gemcitabine	Seems not superior
Schmidt et al. 2012 (CapRI)	Phase III (C)	5-FU, Cisplatin, IFN alfa-2b, RT	Seems not superior

Note: reported efficacy for ESPAC-1 is based on the 2004 update.

Preceding treatment

Surgery

Chemotherapy

Fluorouracil (5-FU) 425 mg/m² IV bolus once per day on days 1 to 5, given second
Folinic acid (Leucovorin) 20 mg/m² IV bolus once per day on days 1 to 5, given first

28-day cycle for 6 cycles

References

ESPAC-1: Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Büchler MW; European Study Group for Pancreatic Cancer. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001 Nov 10;358(9293):1576-85. link to original article PubMed
1. Update: Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler MW; European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004 Mar 18;350(12):1200-10. link to original article contains verified protocol PubMed
ESPAC-3 version 2: Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW; European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010 Sep 8;304(10):1073-81. link to original article contains verified protocol PubMed
CapRI: Schmidt J, Abel U, Debus J, Harig S, Hoffmann K, Herrmann T, Bartsch D, Klein J, Mansmann U, Jäger D, Capussotti L, Kunz R, Büchler MW. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol. 2012 Nov 20;30(33):4077-83. Epub 2012 Sep 24. link to original article contains verified protocol PubMed

Fluorouracil/Fluorouracil & RT

back to top

Fluorouracil/Fluorouracil & RT: Fluorouracil alternating with Fluorouracil & Radiation Therapy

Regimen

Study	Evidence	Comparator	Efficacy
Neoptolemos et al. 2001 (ESPAC-1)	Phase III (E)	1. 5-FU & Leucovorin 2. Observation	Seems to have inferior OS (*)
Neoptolemos et al. 2001 (ESPAC-1)	Phase III (E)	3. 5-FU & RT, then 5-FU & Leucovorin	Not reported
Regine et al. 2008 (RTOG 9704)	Phase III (C)	Gemcitabine/5-FU & RT	Seems not superior (*)

Note: reported efficacy for ESPAC-1 is based on the 2004 update. Reported efficacy for RTOG 9704 is based on the 2011 update.

Preceding treatment

Surgery

Chemotherapy, part 1

Fluorouracil (5-FU) 250 mg/m²/day IV continuous infusion over 21 days, started on day 1 (total dose: 5000 mg/m²)

21-day course, followed in 1 to 2 weeks by:

Chemoradiotherapy

Fluorouracil (5-FU) 250 mg/m²/day IV continuous infusion throughout radiation therapy
Concurrent radiation therapy, 1.8 Gy fractions x 28 fractions given 5 days per week, for a total dose of 50.4 Gy. The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed.

6-week course, followed in 3 to 5 weeks by:

Chemotherapy, part 2

Fluorouracil (5-FU) 250 mg/m²/day IV continuous infusion over 28 days, started on day 1 (total dose per cycle: 7000 mg/m²)

6-week cycle for 2 cycles

References

ESPAC-1: Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Büchler MW; European Study Group for Pancreatic Cancer. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001 Nov 10;358(9293):1576-85. link to original article PubMed
1. Update: Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler MW; European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004 Mar 18;350(12):1200-10. link to original article contains verified protocol PubMed
RTOG 9704: Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, Haddock MG, Schaefer P, Willett CG, Rich TA. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008 Mar 5;299(9):1019-26. link to original article contains verified protocol PubMed
1. Update: Regine WF, Winter KA, Abrams R, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Rich TA, Willett CG. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the US Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 2011 May;18(5):1319-26. Epub 2011 Mar 10. link to original article link to PMC article PubMed

mFOLFIRINOX

back to top

mFOLFIRINOX: modified FOLinic acid, Fluorouracil, IRINotecan, OXaliplatin

Regimen

Study	Evidence	Comparator	Efficacy	Toxicity
Conroy et al. 2018 (NCIC CTG PA.6)	Phase III (E)	Gemcitabine	Superior OS	More toxic

Preceding treatment

Surgery

Chemotherapy

Folinic acid (Leucovorin) 400 mg/m² IV over 2 hours once on day 1, given second
Fluorouracil (5-FU) 2400 mg/m² IV continuous infusion over 46 hours, given fourth
Irinotecan (Camptosar) 150 mg/m² IV over 90 minutes once on day 1, given third
Oxaliplatin (Eloxatin) 85 mg/m² IV over 2 hours once on day 1, given first

14-day cycle for 12 cycles

References

NCIC CTG PA.6: Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018 Dec 20;379(25):2395-2406. link to original article contains verified protocol PubMed

Gemcitabine monotherapy

back to top

Variant #1, 2 out of 3 weeks

Study	Evidence
Landry et al. 2010	Phase II

Preceding treatment

Gemcitabine & RT, then surgery

Chemotherapy

Gemcitabine (Gemzar) 1000 mg/m² IV over 100 minutes once per day on days 1 & 8

21-day cycle for 5 cycles

Variant #2, 3 out of 4 weeks

Study	Evidence	Comparator	Efficacy
Oettle et al. 2007 (CONKO-001)	Phase III (E)	Observation	Seems to have superior OS (*)
Ueno et al. 2009 (JSAP-02)	Phase III (E)	Observation	Superior DFS
Neoptolemos et al. 2010 (ESPAC-3 version 2)	Phase III (E)	Fluorouracil & Leucovorin	Seems not superior
Uesaka et al. 2016 (JASPAC 01)	Phase III (C)	S-1	Inferior OS
Neoptolemos et al. 2017 (ESPAC-4)	Phase III (C)	Capecitabine & Gemcitabine	Seems to have inferior OS
Sinn et al. 2017 (CONKO-005)	Phase III (C)	Erlotinib & Gemcitabine	Seems not superior
Conroy et al. 2018 (NCIC CTG PA.6)	Phase III (C)	mFOLFIRINOX	Inferior OS

Treatment starts day 10 to 42 after surgery or after wound is healed.

Note: efficacy for CONKO-001 is based on the 2013 update.

Preceding treatment

Surgery

Chemotherapy

Gemcitabine (Gemzar) 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15

28-day cycle for up to 6 cycles

References

CONKO-001: Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007 Jan 17;297(3):267-77. link to original article contains verified protocol PubMed
1. Update: Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning MB, Sinn M, Hinke A, Riess H. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013 Oct 9;310(14):1473-81. link to original article PubMed
JSAP-02: Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, Doi R, Monden M, Hatori T, Tanaka M, Shimada M, Kanemitsu K. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer. 2009 Sep 15;101(6):908-15. Epub 2009 Aug 18. link to original article link to original article contains protocol PubMed
Landry J, Catalano PJ, Staley C, Harris W, Hoffman J, Talamonti M, Xu N, Cooper H, Benson AB 3rd. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol. 2010 Jun 1;101(7):587-92. link to original article contains verified protocol link to PMC article PubMed
ESPAC-3 version 2: Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler MW; European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010 Sep 8;304(10):1073-81. link to original article contains verified protocol PubMed
JASPAC 01: Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y; JASPAC 01 Study Group. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016 Jul 16;388(10041):248-57. Epub 2016 Jun 2. link to original article contains verified protocol PubMed
ESPAC-4: Neoptolemos JP, Palmer DH, Ghaneh P, Psarelli EE, Valle JW, Halloran CM, Faluyi O, O'Reilly DA, Cunningham D, Wadsley J, Darby S, Meyer T, Gillmore R, Anthoney A, Lind P, Glimelius B, Falk S, Izbicki JR, Middleton GW, Cummins S, Ross PJ, Wasan H, McDonald A, Crosby T, Ma YT, Patel K, Sherriff D, Soomal R, Borg D, Sothi S, Hammel P, Hackert T, Jackson R, Büchler MW; European Study Group for Pancreatic Cancer. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017 Mar 11;389(10073):1011-1024. Epub 2017 Jan 25. link to original article contains protocol PubMed
CONKO-005: Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, Waldschmidt D, Jacobasch L, Wilhelm M, Rau BM, Grützmann R, Weinmann A, Maschmeyer G, Pelzer U, Stieler JM, Striefler JK, Ghadimi M, Bischoff S, Dörken B, Oettle H, Riess H. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. J Clin Oncol. 2017 Oct 10;35(29):3330-3337. Epub 2017 Aug 17. link to original article contains protocol PubMed
NCIC CTG PA.6: Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi JJ, Lecomte T, Assenat E, Faroux R, Ychou M, Volet J, Sauvanet A, Breysacher G, Di Fiore F, Cripps C, Kavan P, Texereau P, Bouhier-Leporrier K, Khemissa-Akouz F, Legoux JL, Juzyna B, Gourgou S, O'Callaghan CJ, Jouffroy-Zeller C, Rat P, Malka D, Castan F, Bachet JB; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018 Dec 20;379(25):2395-2406. link to original article contains verified protocol PubMed

Gemcitabine/Fluorouracil & RT

back to top

Gemcitabine/Fluorouracil & RT: Gemcitabine alternating with Fluorouracil & Radiation Therapy

Regimen

Study	Evidence	Comparator	Efficacy
Regine et al. 2008 (RTOG 9704)	Phase III (E)	5-FU/5-FU & RT	Seems not superior (*)

Note: reported efficacy is based on the 2011 update.

Preceding treatment

Surgery

Chemotherapy, part 1

Gemcitabine (Gemzar) 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15

21-day course, followed in 1 to 2 weeks by:

Chemoradiotherapy

Fluorouracil (5-FU) 250 mg/m²/day IV continuous infusion throughout radiation therapy
Concurrent radiation therapy, 1.8 Gy fractions x 28 fractions given 5 days per week, for a total dose of 50.4 Gy. The last 5.4 Gy of the 50.4 Gy is limited to the tumor bed.

6-week course, followed in 3 to 5 weeks by:

Chemotherapy, part 2

Gemcitabine (Gemzar) 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15

28-day cycle for 3 cycles

References

RTOG 9704: Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoti MR, Fromm ML, Haddock MG, Schaefer P, Willett CG, Rich TA. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008 Mar 5;299(9):1019-26. link to original article contains verified protocol PubMed
1. Update: Regine WF, Winter KA, Abrams R, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Rich TA, Willett CG. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the US Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol. 2011 May;18(5):1319-26. Epub 2011 Mar 10. link to original article link to PMC article PubMed

Observation

back to top

Regimen

Study	Evidence	Comparator	Efficacy
Klinkenbijl et al. 1999 (EORTC 40891)	Phase III (C)	5-FU & RT	Seems not superior
Neoptolemos et al. 2001 (ESPAC-1)	Phase III (C)	1. 5-FU & Leucovorin	Inferior OS
Neoptolemos et al. 2001 (ESPAC-1)	Phase III (C)	2. 5-FU/5-FU & RT 3. 5-FU & RT, then 5-FU & Leucovorin	Seems to have superior OS
Oettle et al. 2007 (CONKO-001)	Phase III (C)	Gemcitabine	Seems to have inferior OS

No active antineoplastic treatment. Efficacy for ESPAC-1 is based on the 2004 update and efficacy for CONKO-001 is based on 2013 update.

Preceding treatment

Surgery

References

EORTC 40891: Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999 Dec;230(6):776-82. link to original article link to PMC article PubMed
1. Update: Smeenk HG, van Eijck CH, Hop WC, Erdmann J, Tran KC, Debois M, van Cutsem E, van Dekken H, Klinkenbijl JH, Jeekel J. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg. 2007 Nov;246(5):734-40. link to original article PubMed
ESPAC-1: Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Büchler MW; European Study Group for Pancreatic Cancer. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001 Nov 10;358(9293):1576-85. link to original article PubMed
1. Update: Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler MW; European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004 Mar 18;350(12):1200-10. link to original article contains verified protocol PubMed
CONKO-001: Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007 Jan 17;297(3):267-77. link to original article contains verified protocol PubMed
1. Update: Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J, Arning MB, Sinn M, Hinke A, Riess H. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013 Oct 9;310(14):1473-81. link to original article PubMed

S-1 monotherapy

back to top

Regimen

Study	Evidence	Comparator	Efficacy
Uesaka et al. 2016 (JASPAC 01)	Phase III (E)	Gemcitabine	Superior OS

Treatment starts day 10 to 42 after surgery or after wound is healed.

Preceding treatment

Surgery

Chemotherapy

Tegafur, gimeracil, oteracil (S-1) as follows:
- BSA less than 1.25 m²: 40 mg PO twice per day on days 1 to 28
- BSA at least 1.25 m² and less than 1.5 m²: 50 mg PO twice per day on days 1 to 28
- BSA 1.5 m² or more: 60 mg PO twice per day on days 1 to 28

42-day cycle for up to 4 cycles

References

JASPAC 01: Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y; JASPAC 01 Study Group. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016 Jul 16;388(10041):248-57. Epub 2016 Jun 2. link to original article contains verified protocol PubMed

Induction therapy for locally advanced disease, potentially resectable

Docetaxel, Gemcitabine, RT

back to top

RT: Radiation Therapy

Regimen

Study	Evidence
Pipas et al. 2005	Phase II

Chemotherapy

Docetaxel (Taxotere) 65 mg/m² IV over 60 minutes once per day on days 1, 15, 29
Gemcitabine (Gemzar) 4000 mg/m² IV over 30 minutes once per day on days 1, 15, 29

6-week course, followed immediately (day 43) by:

Chemoradiation

Gemcitabine (Gemzar) 50 mg/m² IV over 30 minutes twice per week for 12 doses
- Given Monday/Thursday or Tuesday/Friday. Infusion completed ½ to 2 hours prior to RT.
Concurrent radiation therapy, 1.8 Gy fractions x 25 fractions given 5 days per week, for a total dose of 45 Gy to primary target volume. Then 5.4 Gy boost to secondary target volume of 1- to 1.5-cm margin on all sides, including proven nodal involvement. Total 50.4 Gy in 28 fractions.

Supportive medications

GI prophylaxis with a proton pump inhibitor during chemoradiotherapy

6-week course

References

Pipas JM, Barth RJ Jr, Zaki B, Tsapakos MJ, Suriawinata AA, Bettmann MA, Cates JM, Ripple GH, Sutton JE, Gordon SR, McDonnell CE, Perez RP, Redfield N, Meyer LP, Marshall JF, Cole BF, Colacchio TA. Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol. 2005 Dec;12(12):995-1004. Epub 2005 Nov 1. link to original article contains verified protocol PubMed

Gemcitabine & RT

back to top

RT: Radiation Therapy

Variant #1

Study	Evidence
Takahashi et al. 2013	Phase II

Chemoradiotherapy

Gemcitabine (Gemzar) 1000 mg/m² IV once per day on days 1, 8, 15
Concurrent radiation therapy, 2 Gy per fraction, 5 days per week, 25 fractions, total dose of 50 Gy over 5 weeks.

28-day cycle for 3 cycles (Radiation given over weeks 1-5 only)

Subsequent treatment

Restaging is performed 8 weeks after radiation complete (2 weeks after chemotherapy complete). Resection immediately thereafter, if feasible

Variant #2

Study	Evidence
Landry et al. 2010	Phase II

Chemoradiotherapy

Gemcitabine (Gemzar) 500 mg/m² IV over 50 minutes once per week for 6 weeks
Concurrent radiation therapy, 180 cGy x 22 with 3 cm margin to GTV then 180 cGy x 6 with 2 cm margin to GTV, total 50.4 Gy over 6 weeks

One course

Subsequent treatment

Restaging after radiation complete. 4 to 6 week break, followed by surgery, followed by 4 to 8 week break, then adjuvant gemcitabine

References

Landry J, Catalano PJ, Staley C, Harris W, Hoffman J, Talamonti M, Xu N, Cooper H, Benson AB 3rd. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. J Surg Oncol. 2010 Jun 1;101(7):587-92. link to original article contains verified protocol link to PMC article PubMed
Takahashi H, Ohigashi H, Gotoh K, Marubashi S, Yamada T, Murata M, Ioka T, Uehara H, Yano M, Ishikawa O. Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. Ann Surg. 2013 Dec;258(6):1040-50.link to original article contains verified protocol PubMed

Gemcitabine, Cetuximab, RT

back to top

RT: Radiation Therapy

Regimen

Study	Evidence
Pipas et al. 2012	Phase II

Chemoradiotherapy

Cetuximab (Erbitux) as follows:
- 6 to 8 days prior radiation: 400 mg/m² IV over 2 hours once
- During radiation: 250 mg/m² IV over 60 minutes once per week for 6 doses
Gemcitabine (Gemzar) 50 mg/m² IV over 30 minutes twice per week for 12 doses
- Given Monday/Thursday or Tuesday/Friday. Infusion completed ½ to 2 hours prior to RT.
Concurrent radiation therapy, delivered using IMRT. Gross tumor volume (GTV) was all known disease including imaging proven nodal disease. The primary planning target volume (PTV1) included the GTV with 2- to 3-cm margins in all directions as well as potential nodal involvement. Secondary planning target volume (PTV2) included the GTV with 1- to 1.5-cm margins on all sides including proven nodal involvement. Tertiary planning treatment volume (PTV3) included the area of the GTV adjacent to the vascular structures specifically the mesenteric and portal vessels with a 0.5-cm margin. The prescription dose delivered to PTV3 was 54 Gy in 28 fractions. Synchronously, PTV1 and PTV2 received 45 and 50.4 Gy, respectively. All fields were treated daily at five fractions per week.

Supportive medications

GI prophylaxis with a proton pump inhibitor during chemoradiotherapy

6-week course

One month following therapy, patients were restaged with CT scan of chest/abdomen/pelvis. Patients deemed to be candidates for surgical resection were offered laparotomy ∼6 to 10 weeks after completion of neoadjuvant therapy.

References

Pipas JM, Zaki BI, McGowan MM, Tsapakos MJ, Ripple GH, Suriawinata AA, Tsongalis GJ, Colacchio TA, Gordon SR, Sutton JE, Srivastava A, Smith KD, Gardner TB, Korc M, Davis TH, Preis M, Tarczewski SM, Mackenzie TA, Barth RJ Jr. Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma. Ann Oncol. 2012 Nov;23(11):2820-7. Epub 2012 May 9. link to original article contains verified protocol link to PMC article PubMed

FOLFIRINOX/modified FOLFIRINOX +/- Chemoradiation

Study	Evidence
Murphy et al. 2018	Phase II

Note: FOLFIRINOX should be limited to those with ECOG 0-1

Chemotherapy

Folinic acid (Leucovorin) 400 mg/m² IV over 2 hours once on day 1, given second
Fluorouracil (5-FU) 400 mg/m² IV bolus once on day 1, then 2400 mg/m² IV continuous infusion over 46 hours, given fourth (total dose per cycle: 2800 mg/m²)
Irinotecan (Camptosar) 180* mg/m² IV over 90 minutes once on day 1, given third with the last 90 minutes of leucovorin; that is, irinotecan starts 30 minutes after the start of leucovorin
Oxaliplatin (Eloxatin) 85 mg/m² IV over 2 hours once on day 1, given first

Supportive medications

Pegfilgrastim (Neulasta) 6 mg SC once on day 4

14-day cycle for 8* cycles

*Amendment after first 6 patients were enrolled increased neoadjuvant cycles from 4 to 8 if no progression was detected on restaging CT

Followed by restaging with CT scan. If tumor was resectable (no vascular involvement), they received short-course proton chemoradiotherapy:

Proton Chemoradiotherapy

Capecitabine 825 mg/m² PO BID, Monday – Friday for 2 weeks
Proton radiotherapy of 25 GyE in 5 treatments OR Intensity modulated radiotherapy (IMRT) of 30 Gy in 10 fractions

References

Murphy J.E., Wo J.Y., Ryan D.P., Jiang W., Yeap B.Y., Drapek L.C., Blaszkowsky L.S., Kwak E.L., Allen J.N., Clark J.W., et al. Total neoadjuvant therapy with folfirinox followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: A phase 2 clinical trial. JAMA Oncol. 2018; 4:963–969. doi: 10.1001/jamaoncol.2018.0329. Link to original article: https://jamanetwork.com/journals/jamaoncology/fullarticle/2679565 contains verified protocol Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/29800971

mFOLFIRINOX, Gemcitabine, RT

back to top

mFOLFIRINOX, Gemcitabine, RT: modified FOLinic acid, Fluorouracil, IRINotecan, OXaliplatin, Gemcitabine, Radiation Therapy

Variant #1

Study	Evidence
Blazer et al. 2015	Retrospective

Chemotherapy, mFOLFIRINOX portion

Fluorouracil (5-FU) 1200 mg/m²/day IV continuous infusion over 46 hours, started on day 1 (total dose per cycle: 2400 mg/m²)
Irinotecan (Camptosar) 165 mg/m² IV over 90 minutes once on day 1
Oxaliplatin (Eloxatin) 85 mg/m² IV over 2 to 4 hours once on day 1

Supportive medications

Pegfilgrastim (Neulasta) 6 mg SC once on day 4

14-day cycle for 4 to 8 cycles

Followed by complete restaging. If tumor localized but still not resectable, chemoradiotherapy was administered:

Chemoradiotherapy

Gemcitabine (Gemzar) 1000 mg/m² IV once per week
External beam radiotherapy was 36 Gy in 15 daily fractions

3-week course

Variant #2

Study	Evidence
Hosein et al. 2012	Retrospective

Chemotherapy, mFOLFIRINOX portion

Folinic acid (Leucovorin) 400 mg/m² IV once on day 1
Fluorouracil (5-FU) 400 mg/m² IV bolus once on day 1, then 2400 mg/m² IV continuous infusion over 46 hours (total dose per cycle: 2800 mg/m²)
Irinotecan (Camptosar) 180 mg/m² IV once on day 1
Oxaliplatin (Eloxatin) 85 mg/m² IV once on day 1

14-day cycles. Protocol followed "per ACCORD-11 trial." Filgrastim was given at the discretion of the treating physician.

Treatment stopped at maximum response or tolerability. Resectable patients by imaging criteria were offered surgery, followed by postoperative chemoradiotherapy. Unresectable patients were offered chemoradiotherapy, followed by surgery (if they became resectable):

Chemoradiotherapy

Gemcitabine (Gemzar) 600 mg/m² IV once per week
External beam radiotherapy at 50.4 Gy in 28 fractions.

6-week course

References

Retrospective: Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, Narayanan G, Ribeiro A, Portelance L, Merchan JR, Levi JU, Rocha-Lima CM. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012 May 29;12:199. link to original article link to PMC article PubMed
Retrospective: Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Christopher Ellison E, Bloomston M, Bekaii-Saab T. Neoadjuvant Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC) and Borderline Resectable (BRPC) Adenocarcinoma of the Pancreas. Ann Surg Oncol. 2015 Apr;22(4):1153-9. link to original article link to PMC article PubMed

Induction therapy for locally advanced disease, unresectable

Capecitabine monotherapy

back to top

Regimen

Study	Evidence
Cartwright et al. 2002	Phase II

Chemotherapy

Capecitabine (Xeloda) 1250 mg/m² PO twice per day on days 1 to 14

21-day cycle for up to 1 year

References

Cartwright TH, Cohn A, Varkey JA, Chen YM, Szatrowski TP, Cox JV, Schulz JJ. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol. 2002 Jan 1;20(1):160-4. link to original article contains verified protocol PubMed

Erlotinib & Gemcitabine

back to top

Variant #1, Gem 3 out of 4 weeks x 4

Study	Evidence	Comparator	Efficacy
Hammel et al. 2016 (GERCOR LAP07)	Phase III (E)	See link	See link

Chemotherapy

Erlotinib (Tarceva) 100 mg PO once per day
Gemcitabine (Gemzar) 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15

28-day cycle for 4 cycles

Subsequent treatment

Patients without progression: Erlotinib & Gemcitabine x 2 more cycles (6 total) versus Capecitabine, Erlotinib, RT

Variant #2, Gem 3 out of 4 weeks x 6

Study	Evidence	Comparator	Efficacy
Hammel et al. 2016 (GERCOR LAP07)	Phase III (E)	See link	See link

Note: it is not clear from the protocol whether erlotinib is continued beyond the end of chemotherapy.

Chemotherapy

Erlotinib (Tarceva) as follows:
- Cycles 1 to 4: 100 mg PO once per day
- Cycles 5 & 6: 150 mg PO once per day
Gemcitabine (Gemzar) 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15

28-day cycle for 6 cycles

Variant #3, gemcitabine lead-in, erlotinib 100 mg/day

FDA-recommended dose

Study	Evidence	Comparator	Efficacy
Moore et al. 2007 (NCIC CTG PA.3)	Phase III (E)	Gemcitabine	Seems to have superior OS

Chemotherapy

Erlotinib (Tarceva) 100 mg PO once per day
Gemcitabine (Gemzar) as follows:
- Cycle 1: 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15, 22, 29, 36, 43
- Cycle 2 onwards: 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15

One 8-week cycle, then 28-day cycles

Variant #4, gemcitabine lead-in, erlotinib 150 mg/day

Study	Evidence	Comparator	Efficacy
Moore et al. 2007 (NCIC CTG PA.3)	Phase III (E)	Gemcitabine	Not reported

Note: due to low accrual, the efficacy of this arm could not be determined.

Chemotherapy

Erlotinib (Tarceva) 150 mg PO once per day
Gemcitabine (Gemzar) as follows:
- Cycle 1: 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15, 22, 29, 36, 43
- Cycle 2 onwards: 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15

One 8-week cycle, then 28-day cycles

References

NCIC CTG PA.3: Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 May 20;25(15):1960-6. Epub 2007 Apr 23. link to original article contains verified protocol PubMed
GERCOR LAP07: Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouché O, Shannon J, André T, Mineur L, Chibaudel B, Bonnetain F, Louvet C; LAP07 Trial Group. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: The LAP07 randomized clinical trial. JAMA. 2016 May 3;315(17):1844-53. link to original article contains verified protocol PubMed

Fluorouracil & RT

back to top

RT: Radiation Therapy

Regimen

Study	Evidence	Comparator	Efficacy
Moertel et al. 1981	Phase III (E)	RT	Superior OS
Herman et al. 2013	Phase III (C)	Fluorouracil & RT with TNFerade	Seems not superior

Chemoradiotherapy

Fluorouracil (5-FU) 200 mg/m²/day IV continuous infusion over 120 hours, started on Mondays (total dose per week: 1000 mg/m²)
Concurrent radiation therapy, 50.4 Gy total: 1.80 Gy fractions x 25 fractions given 5 days per week, for a total dose of 45 Gy, followed by 1.80 Gy x 3 fractions boost to the tumor bed.

One course

Subsequent treatment

Herman et al. 2013: Gemcitabine or Erlotinib & Gemcitabine maintenance, starting four weeks after chemoradiotherapy

References

Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knowlton A, Kalser M, Barkin J, Lessner H, Mann-Kaplan R, Ramming K, Douglas HO Jr, Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson JM, Zamcheck N, Novak JW. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer. 1981 Oct 15;48(8):1705-10. link to original article PubMed
Herman JM, Wild AT, Wang H, Tran PT, Chang KJ, Taylor GE, Donehower RC, Pawlik TM, Ziegler MA, Cai H, Savage DT, Canto MI, Klapman J, Reid T, Shah RJ, Hoffe SE, Rosemurgy A, Wolfgang CL, Laheru DA. Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results. J Clin Oncol. 2013 Mar 1;31(7):886-94. Epub 2013 Jan 22. link to original article contains verified protocol link to PMC article PubMed

Gemcitabine monotherapy

back to top

Variant #1, 3 out of 4 weeks x 4

Study	Evidence	Comparator	Efficacy
Hammel et al. 2016 (GERCOR LAP07)	Phase III (C)	See link	See link

Chemotherapy

Gemcitabine (Gemzar) 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15

28-day cycle for 4 cycles

Subsequent treatment

Patients without progression: Gemcitabine x 2 more cycles (6 total) versus Capecitabine & RT

Variant #2, 3 out of 4 weeks x 6

Study	Evidence	Comparator	Efficacy
Hammel et al. 2016 (GERCOR LAP07)	Phase III (C)	See link	See link

Chemotherapy

Gemcitabine (Gemzar) 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15

28-day cycle for 6 cycles

Variant #3, 8-week lead-in ("Burris regimen")

Study	Evidence	Comparator	Efficacy
Cantore et al. 2004	Phase III (C)	Intraarterial FLEC	Seems to have inferior OS
Louvet et al. 2005	Phase III (C)	GemOx	Seems to have inferior PFS
Chauffert et al. 2008 (FFCD/SFRO 2000-01)	Phase III (E)	CF & RT, then Gemcitabine	Might have superior OS
Loehrer et al. 2011 (ECOG E4201)	Phase III (C)	Gemcitabine & RT	Seems to have inferior OS

Chemotherapy

Gemcitabine (Gemzar) as follows:
- First 8 weeks: 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15, 22, 29, 36, 43
- Subsequent 4-week cycles: 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15

Continued for at least 3 months

Subsequent treatment

Louvet et al. 2005: 5-FU & RT consolidation was recommended but not mandated

References

Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Rabbi C, Marangolo M. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. J Chemother. 2004 Dec;16(6):589-94. link to original article contains protocol PubMed
Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A; GERCOR; GISCAD. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005 May 20;23(15):3509-16. link to original article contains verified protocol PubMed
FFCD/SFRO 2000-01: Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, Bosset JF, Aparicio T, Mineur L, Azzedine A, Hammel P, Butel J, Stremsdoerfer N, Maingon P, Bedenne L. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer: definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol. 2008 Sep;19(9):1592-9. Epub 2008 May 7. link to original article contains protocol PubMed
ECOG E4201: Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR, Benson AB 3rd. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011 Nov 1;29(31):4105-12. Epub 2011 Oct 3. link to original article contains verified protocol link to PMC article PubMed
GERCOR LAP07: Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouché O, Shannon J, André T, Mineur L, Chibaudel B, Bonnetain F, Louvet C; LAP07 Trial Group. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: The LAP07 randomized clinical trial. JAMA. 2016 May 3;315(17):1844-53. link to original article contains verified protocol PubMed

Gemcitabine & RT

back to top

RT: Radiation Therapy

Variant #1 (600 mg/m²)

Study	Evidence	Comparator	Efficacy
Cardenes et al. 2011	Phase II
Loehrer et al. 2011 (ECOG E4201)	Phase III (E)	Gemcitabine	Seems to have superior OS

Chemoradiotherapy

Gemcitabine (Gemzar) 600 mg/m² IV over 30 to 60 minutes once per week during radiation
Concurrent radiation therapy, 1.8 Gy per fraction, 5 days per week, 28 fractions, total dose of 50.4 Gy over 5.5 weeks.

One course, followed in 4 weeks by:

Maintenance chemotherapy

Gemcitabine (Gemzar) 1000 mg/m² IV over 30 minutes once per week, 3 out of 4 weeks

28-day cycle for up to 5 cycles

Variant #2 (400 mg/m²)

Study	Evidence
Epelbaum et al. 2002	Phase II

Chemotherapy

Gemcitabine (Gemzar) 1000mg/m² IV over 30 minutes once per week for 7 weeks

Radiation planning during this phase, followed by:

Chemoradiotherapy

Gemcitabine (Gemzar) 400 mg/m² IV over 30 minutes once per week (days 1, 8, 15)
Concurrent radiation therapy, 5 days per week, 28 fractions, total dose of 50.4 Gy over 5.5 weeks

28 day cycle for 2 cycles, followed by:

Maintenance chemotherapy

Gemcitabine (Gemzar) 1000mg/m² IV over 30 minutes once per week, 3 out of 4 weeks

28-day cycles

References

Epelbaum R, Rosenblatt E, Nasrallah S, Faraggi D, Gaitini D, Mizrahi S, Kuten A. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol. 2002 Nov;81(3):138-43. link to original article contains verified protocol PubMed
Cardenes HR, Moore AM, Johnson CS, Yu M, Helft P, Chiorean EG, Vinson J, Howard TJ, Stephens AW, Tai DF, Loehrer PJ Sr. A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study. Am J Clin Oncol. 2011 Oct;34(5):460-5.link to original article PubMed
ECOG E4201: Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P, Ramanathan RK, Crane CH, Alberts SR, Benson AB 3rd. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011 Nov 1;29(31):4105-12. link to original article contains verified protocol link to PMC article PubMed

GemOx

back to top

GemOx: Gemcitabine, Oxaliplatin

Regimen

Study	Evidence	Comparator	Efficacy
Louvet et al. 2005	Phase III (E)	Gemcitabine	Seems to have superior PFS

Chemotherapy

Gemcitabine (Gemzar) 1000 mg/m² IV over 100 minutes once on day 1
Oxaliplatin (Eloxatin) 100 mg/m² IV over 2 hours once on day 2

14-day cycle for at least 3 months

Subsequent chemoradiotherapy (45 Gy in 25 fractions for 5 weeks, associated with a daily FU 250 mg/m² continuous infusion, and a boost of 10 Gy in 8 fractions restricted to the initial tumor volume) was recommended but not mandated.

References

Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A; GERCOR; GISCAD. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005 May 20;23(15):3509-16. link to original article contains verified protocol PubMed

Radiation therapy

back to top

Regimen

Study	Evidence	Comparator	Efficacy
Cohen et al. 2005 (ECOG E8282)	Phase III (C)	5-FU, MMC, RT	Seems not superior

Radiotherapy

External beam radiotherapy

References

ECOG E8282: Cohen SJ, Dobelbower R Jr, Lipsitz S, Catalano PJ, Sischy B, Smith TJ, Haller DG; Eastern Cooperative Oncology Group. A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1345-50. link to original article PubMed

Metastatic disease, first-line

Capecitabine monotherapy

back to top

Regimen

Study	Evidence
Cartwright et al. 2002	Phase II

Chemotherapy

Capecitabine (Xeloda) 1250 mg/m² PO twice per day on days 1 to 14

21-day cycle for up to 1 year

References

Cartwright TH, Cohn A, Varkey JA, Chen YM, Szatrowski TP, Cox JV, Schulz JJ. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol. 2002 Jan 1;20(1):160-4. link to original article contains verified protocol PubMed

Capecitabine & Gemcitabine

back to top

GemCap/GEM-CAP: Gemcitabine & Capecitabine

Variant #1

Study	Evidence	Comparator	Efficacy
Lee et al. 2017	Phase III (E)	Gemcitabine	Might have superior OS

Note: this is essentially identical to the maintenance phase of variant #2, below.

Chemotherapy

Capecitabine (Xeloda) 1660 mg/m²/day PO on days 1 to 21 (frequency of dosing not specified)
Gemcitabine (Gemzar) 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15

28-day cycles

Variant #2

Study	Evidence	Comparator	Efficacy
Cunningham et al. 2009	Phase III (E)	Gemcitabine	Superior PFS

Initial chemotherapy

Capecitabine (Xeloda) 830 mg/m² PO twice per day on days 1 to 21, 29 to 49
Gemcitabine (Gemzar) 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15, 22, 29, 36, 43

8-week course, followed by:

Maintenance chemotherapy

Capecitabine (Xeloda) 830 mg/m² PO twice per day on days 1 to 21
Gemcitabine (Gemzar) 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15

28-day cycles

Variant #3

Study	Evidence	Comparator	Efficacy
Herrmann et al. 2007 (SAKK 44/00-CECOG/PAN.1.3.001)	Phase III (E)	Gemcitabine	Seems not superior

Chemotherapy

Capecitabine (Xeloda) 650 mg/m² PO twice per day on days 1 to 14
Gemcitabine (Gemzar) 1000 mg/m² IV over 30 minutes once per day on days 1 & 8

21-day cycle for up to 24 weeks

References

SAKK 44/00-CECOG/PAN.1.3.001: Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W; Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007 Jun 1;25(16):2212-7. link to original article contains verified protocol PubMed
1. CBR/QoL analysis: Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi BC, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Herrmann R; Central European Cooperative Oncology Group. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol. 2008 Aug 1;26(22):3695-701. link to original article contains verified protocol PubMed
Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009 Nov 20;27(33):5513-8. Epub 2009 Oct 26. link to original article contains verified protocol PubMed
Lee HS, Chung MJ, Park JY, Bang S, Park SW, Kim HG, Noh MH, Lee SH, Kim YT, Kim HJ, Kim CD, Lee DK, Cho KB, Cho CM, Moon JH, Kim DU, Kang DH, Cheon YK, Choi HS, Kim TH, Kim JK, Moon J, Shin HJ, Song SY; Korean Society of Gastrointestinal Cancer. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea. Medicine (Baltimore). 2017 Jan;96(1):e5702. contains verified protocol link to PMC article PubMed

Cisplatin & Gemcitabine

back to top

Variant #1, 25/1000, weekly dosing

Study	Evidence	Comparator	Efficacy
Colucci et al. 2002	Phase III (E)	Gemcitabine	Seems to have superior TTP
Colucci et al. 2010 (GIP-1)	Phase III (E)	Gemcitabine	Seems not superior

Note that cisplatin is not given on day 22 of the first 8 weeks; otherwise, the schedule is identical to the schedule for gemcitabine. Treatment in Colucci et al. 2002 is given for a total of 3 cycles (16 weeks).

Chemotherapy

Cisplatin (Platinol) as follows, given first, 60 minutes prior to gemcitabine:
- First 8 weeks: 25 mg/m² IV once per day on days 1, 8, 15, 29, 36, 43
- Subsequent cycles: 25 mg/m² IV once per day on days 1, 8, 15
Gemcitabine (Gemzar) as follows, given second:
- First 8 weeks: 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15, 22, 29, 36, 43
- Subsequent cycles: 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15

28-day cycles

Variant #2, 35/1000, 2 out of 3 weeks

Study	Evidence	Comparator	Efficacy
Cascinu et al. 2008	Randomized Phase II (C)	Cisplatin, Gemcitabine, Cetuximab	Seems not superior

Chemotherapy

Cisplatin (Platinol) 35 mg/m² IV over 30 minutes once per day on days 1 & 8 (with 1500 mL NS)
Gemcitabine (Gemzar) 1000 mg/m² IV over 30 minutes once per day on days 1 & 8

21-day cycles

Variant #3, 50/1000, bi-weekly dosing

Study	Evidence	Comparator	Efficacy
Heinemann et al. 2006	Phase III (E)	Gemcitabine	Might have superior PFS

Chemotherapy

Cisplatin (Platinol) 50 mg/m² IV over 60 minutes once per day on days 1 & 15
Gemcitabine (Gemzar) 1000 mg/m² IV over 30 minutes once per day on days 1 & 15

28-day cycles

References

Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E, Lopez M. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer. 2002 Feb 15;94(4):902-10. link to original article contains protocol PubMed
Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006 Aug 20;24(24):3946-52. link to original article contains verified regimen PubMed
Cascinu S, Berardi R, Labianca R, Siena S, Falcone A, Aitini E, Barni S, Di Costanzo F, Dapretto E, Tonini G, Pierantoni C, Artale S, Rota S, Floriani I, Scartozzi M, Zaniboni A; Italian Group for the Study of Digestive Tract Cancer (GISCAD). Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol. 2008 Jan;9(1):39-44. link to original article contains protocol PubMed
GIP-1: Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, Perrone F; Gruppo Oncologico Italia Meridionale (GOIM); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010 Apr 1;28(10):1645-51. link to original article contains verified protocol PubMed

Erlotinib & Gemcitabine

back to top

Variant #1, no gemcitabine lead-in

Study	Evidence	Comparator	Efficacy
Kordes et al. 2015	Randomized Phase II (C)	Erlotinib, Gemcitabine, Metformin	Seems not superior

Chemotherapy

Erlotinib (Tarceva) 100 mg PO once per day
Gemcitabine (Gemzar) 1000 mg/m² IV once per day on days 1, 8, 15

28-day cycles

Variant #2, gemcitabine lead-in, erlotinib 100 mg/day

FDA-recommended dose

Study	Evidence	Comparator	Efficacy
Moore et al. 2007 (NCIC CTG PA.3)	Phase III (E)	Gemcitabine	Seems to have superior OS
Van Cutsem et al. 2009	Phase III (C)	Erlotinib, Gemcitabine, Bevacizumab	Seems not superior

Chemotherapy

Erlotinib (Tarceva) 100 mg PO once per day
Gemcitabine (Gemzar) as follows:
- Cycle 1: 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15, 22, 29, 36, 43
- Cycle 2 onwards: 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15

One 8-week cycle, then 28-day cycles

Variant #3, gemcitabine lead-in, erlotinib 150 mg/day

Study	Evidence	Comparator	Efficacy
Moore et al. 2007 (NCIC CTG PA.3)	Phase III (E)	Gemcitabine	Not reported
Heinemann et al. 2012 (AIO-PK0104)	Phase III (C)	Capecitabine & Erlotinib	Superior TTF1

Note: due to low accrual in NCIC CTG PA.3, the efficacy of this arm could not be determined.

Chemotherapy

Erlotinib (Tarceva) 150 mg PO once per day
Gemcitabine (Gemzar) as follows:
- Cycle 1: 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15, 22, 29, 36, 43
- Cycle 2 onwards: 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15

One 8-week cycle, then 28-day cycles

References

NCIC CTG PA.3: Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 May 20;25(15):1960-6. Epub 2007 Apr 23. link to original article contains verified protocol PubMed
Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J, Moore MJ. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009 May 1;27(13):2231-7. Epub 2009 Mar 23. link to original article contains verified protocol PubMed
AIO-PK0104: Heinemann V, Vehling-Kaiser U, Waldschmidt D, Kettner E, Märten A, Winkelmann C, Klein S, Kojouharoff G, Gauler TC, von Weikersthal LF, Clemens MR, Geissler M, Greten TF, Hegewisch-Becker S, Rubanov O, Baake G, Höhler T, Ko YD, Jung A, Neugebauer S, Boeck S. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104). Gut. 2013 May;62(5):751-9. Epub 2012 Jul 7. link to original article contains verified protocol' PubMed
Kordes S, Pollak MN, Zwinderman AH, Mathôt RA, Weterman MJ, Beeker A, Punt CJ, Richel DJ, Wilmink JW. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2015 Jul;16(7):839-47. Epub 2015 Jun 8. link to original articlecontains protocol PubMed

Fluorouracil monotherapy

back to top

Variant #1, 300 mg/m²/day PVI

Study	Evidence	Comparator	Efficacy
Maisey et al. 2002	Phase III (C)	5-FU & Mitomycin	Seems not superior

Chemotherapy

Fluorouracil (5-FU) 300 mg/m²/day IV continuous infusion

Continued for up to 24 weeks

Variant #2, 500 mg/m² intermittent

Study	Evidence	Comparator	Efficacy
Cullinan et al. 1985	Phase III (E)	1. FA 2. FAM	Seems not superior
Cullinan et al. 1990	Phase III (C)	1. Mallinson regimen 2. FAP	Seems not superior

Note: this is an experimental arm that did not meet its primary endpoint; included here because it was eventually used to establish this regimen as a standard comparator.

Chemotherapy

Fluorouracil (5-FU) 500 mg/m² IV once per day on days 1 to 5

28-day cycle for 2 cycles, then 35-day cycles

Variant #2, 600 mg/m² weekly

Study	Evidence	Comparator	Efficacy
Burris et al. 1997	Phase III (C)	Gemcitabine	Inferior OS

Inferior to gemcitabine. Here for historical reference purposes, only.

Chemotherapy

Fluorouracil (5-FU) 600 mg/m² IV once per week

Continued indefinitely

References

Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, Windschitl HE, Twito DI, Marschke RF, Foley JF, Pfeifle DM, Barlow JF. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA. 1985 Apr 12;253(14):2061-7. link to original article PubMed
Cullinan S, Moertel CG, Wieand HS, Schutt AJ, Krook JE, Foley JF, Norris BD, Kardinal CG, Tschetter LK, Barlow JF. A phase III trial on the therapy of advanced pancreatic carcinoma: evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer. 1990 May 15;65(10):2207-12. link to original article PubMed
Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 Jun;15(6):2403-13. link to original article contains verified protocol PubMed
Maisey N, Chau I, Cunningham D, Norman A, Seymour M, Hickish T, Iveson T, O'Brien M, Tebbutt N, Harrington A, Hill M. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol. 2002 Jul 15;20(14):3130-6. link to original article contains protocol PubMed

FOLFIRINOX

back to top

FOLFIRINOX: FOLinic acid, Fluorouracil, IRINotecan, OXaliplatin

Regimen

Study	Evidence	Comparator	Efficacy	Toxicity
Conroy et al. 2011 (PRODIGE 4/ACCORD 11)	Phase III (E)	Gemcitabine	Superior OS	Superior QoL by EORTC QLQ-C30

Chemotherapy

Folinic acid (Leucovorin) 400 mg/m² IV over 2 hours once on day 1, given second
Fluorouracil (5-FU) 400 mg/m² IV bolus once on day 1, then 2400 mg/m² IV continuous infusion over 46 hours, given fourth (total dose per cycle: 2800 mg/m²)
Irinotecan (Camptosar) 180 mg/m² IV over 90 minutes once on day 1, given third with the last 90 minutes of leucovorin; that is, irinotecan starts 30 minutes after the start of leucovorin
Oxaliplatin (Eloxatin) 85 mg/m² IV over 2 hours once on day 1, given first

14-day cycles

References

PRODIGE 4/ACCORD 11: Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817-25. link to original article contains verified protocol PubMed
1. QoL analysis: Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Boige V, Bérille J, Conroy T. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2013 Jan 1;31(1):23-9. Epub 2012 Dec 3. link to original article PubMed

Gemcitabine monotherapy

back to top

Variant #1, 900 mg/m², 3 out of 4 weeks

Study	Evidence	Comparator	Efficacy
Stathopoulos et al. 2006	Phase III (C)	Gemcitabine & Irinotecan	Seems not superior

Chemotherapy

Gemcitabine (Gemzar) 900 mg/m² IV once per day on days 1, 8, 15

28-day cycles

Variant #2, 1000 mg/m², 8-week lead-in ("Burris regimen")

Study	Evidence	Comparator	Efficacy
Burris et al. 1997	Phase III (E)	5-FU	Superior OS
Colucci et al. 2002	Phase III (C)	Cisplatin & Gemcitabine	Seems to have inferior TTP
Moore et al. 2003 (NCIC CTG PA.1)	Phase III (C)	Tanomastat	Superior OS
Van Cutsem et al. 2004	Phase III (C)	Gemcitabine & Tipifarnib	Seems not superior
Rocha Lima et al. 2004	Phase III (C)	Gemcitabine & Irinotecan	Seems not superior
Louvet et al. 2005	Phase III (C)	GemOx	Seems to have inferior PFS
Reni et al. 2005	Phase III (C)	PEFG	Seems to have inferior PFS
Abou-Alfa et al. 2006a	Phase III (C)	Gemcitabine & Exatecan	Seems not superior
Moore et al. 2007 (NCIC CTG PA.3)	Phase III (C)	Erlotinib & Gemcitabine	Seems to have inferior OS
Herrmann et al. 2007 (SAKK 44/00-CECOG/PAN.1.3.001)	Phase III (C)	GemCap	Seems not superior
Poplin et al. 2009 (ECOG E6201)	Phase III (C)	1. GEM FDR	Might have inferior OS
Poplin et al. 2009 (ECOG E6201)	Phase III (C)	2. GEMOX	Seems not superior
Cunningham et al. 2009	Phase III (C)	GEM-CAP	Inferior PFS
Colucci et al. 2010 (GIP-1)	Phase III (C)	Cisplatin & Gemcitabine	Seems not superior
Philip et al. 2010 (SWOG S0205)	Phase III (C)	Gemcitabine & Cetuximab	Seems not superior
Dahan et al. 2010 (FFCD 0301)	Phase III (C)	LV5FU2-CDDP	Seems not superior
Conroy et al. 2011 (PRODIGE 4/ACCORD 11)	Phase III (C)	FOLFIRINOX	Inferior OS
Gonçalves et al. 2012 (BAYPAN)	Phase III (C)	Gemcitabine & Sorafenib	Seems not superior
Rougier et al. 2013	Phase III (C)	Gemcitabine & Ziv-aflibercept	Seems not superior
Von Hoff et al. 2013 (MPACT)	Phase III (C)	Gemcitabine & nab-Paclitaxel	Inferior OS
Deplanque et al. 2015 (AB07012)	Phase III (C)	Gemcitabine & Masitinib	Seems not superior
Middleton et al. 2017 (ViP)	Randomized Phase II (C)	Gemcitabine & Vandetanib	Seems not superior

Note: Colucci et al. 2002 stopped treatment after 3 cycles (16 weeks).

Chemotherapy

Gemcitabine (Gemzar) as follows:
- First 8 weeks: 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15, 22, 29, 36, 43
- Subsequent cycles: 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15
  - In Burris et al. 1997, patients with grade 2 or lower toxicities could have had doses increased to 1250 mg/m²

28-day cycles

Variant #3, 1000 mg/m², 3 out of 4 weeks

Study	Evidence	Comparator	Efficacy
Berlin et al. 2002 (ECOG E2297)	Phase III (C)	5-FU & Gemcitabine	Might have inferior OS
Oettle et al. 2005	Phase III (C)	Gemcitabine & Pemetrexed	Seems not superior
Heinemann et al. 2006	Phase III (C)	Cisplatin & Gemcitabine	Might have inferior PFS
Spano et al. 2008 (A4061016)	Randomized Phase II (C)	Gemcitabine & Axitinib	Seems not superior
Kindler et al. 2010 (CALGB 80303)	Phase III (C)	Gemcitabine & Bevacizumab	Seems not superior
Kindler et al. 2011 (A4061028)	Phase III (C)	Gemcitabine & Axitinib	Seems not superior
Ueno et al. 2013 (GEST)	Phase III (C)	1. S-1	Non-inferior OS
Ueno et al. 2013 (GEST)	Phase III (C)	2. Gemcitabine & S-1	Seems not superior
Fuchs et al. 2015 (GAMMA)	Randomized Phase Ib/II (C)	Gemcitabine & Ganitumab	Seems not superior
O'Neil et al. 2015	Phase II/III (C)	Gemcitabine & Rigosertib	Seems not superior
Catenacci et al. 2015	Randomized Phase Ib/II (C)	Gemcitabine & Vismodegib	Seems not superior
Lee et al. 2017	Phase III (C)	GemCap	Might have inferior OS

Chemotherapy

Gemcitabine (Gemzar) 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15

28-day cycles

Variant #4, 1000 mg/m², weekly

Study	Evidence	Comparator	Efficacy
Hong et al. 2013	Randomized Phase II (C)	Gemcitabine & Simvastatin	Seems not superior

Chemotherapy

Gemcitabine (Gemzar) 1000 mg/m² IV over 30 minutes once per day on days 1, 8, 15

21-day cycles

Variant #5, 1500 mg/m², fixed-dose rate (FDR)

Study	Evidence	Comparator	Efficacy
Poplin et al. 2009 (ECOG E6201)	Phase III (E)	1. Gemcitabine	Might have superior OS
Poplin et al. 2009 (ECOG E6201)	Phase III (E)	2. GEMOX	Not reported

Chemotherapy

Gemcitabine (Gemzar) 1500 mg/m² IV over 150 minutes (10 mg/m²/min) once per day on days 1, 8, 15

28-day cycles

References

Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997 Jun;15(6):2403-13. link to original article contains verified protocol PubMed
Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E, Lopez M. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer. 2002 Feb 15;94(4):902-10. link to original article contains protocol PubMed
ECOG E2297: Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Benson AB 3rd. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002 Aug 1;20(15):3270-5. link to original article contains protocol PubMed
NCIC CTG PA.1: Moore MJ, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A, Hagan K, Greenberg B, Colwell B, Zee B, Tu D, Ottaway J, Humphrey R, Seymour L; National Cancer Institute of Canada Clinical Trials Group. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003 Sep 1;21(17):3296-302. link to original article contains protocol PubMed
Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruixo J, Ma Y, Von Hoff D. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004 Apr 15;22(8):1430-8. link to original article contains protocol PubMed
Rocha Lima CM, Green MR, Rotche R, Miller WH Jr, Jeffrey GM, Cisar LA, Morganti A, Orlando N, Gruia G, Miller LL. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004 Sep 15;22(18):3776-83. link to original article contains protocol PubMed
Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A; GERCOR; GISCAD. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005 May 20;23(15):3509-16. link to original article contains verified protocol PubMed
Oettle H, Richards D, Ramanathan RK, van Laethem JL, Peeters M, Fuchs M, Zimmermann A, John W, Von Hoff D, Arning M, Kindler HL. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005 Oct;16(10):1639-45. Epub 2005 Aug 8. Erratum in: Ann Oncol. 2006 Mar;17(3):535. link to original article contains protocol PubMed
Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005 Jun;6(6):369-76. link to original article contains protocol PubMed
Stathopoulos GP, Syrigos K, Aravantinos G, Polyzos A, Papakotoulas P, Fountzilas G, Potamianou A, Ziras N, Boukovinas J, Varthalitis J, Androulakis N, Kotsakis A, Samonis G, Georgoulias V. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer. 2006 Sep 4;95(5):587-92. Epub 2006 Aug 8. link to original article link to PMC article contains protocol PubMed
Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006 Aug 20;24(24):3946-52. link to original article contains verified regimen PubMed
Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian NS, Feit K, Ackerman J, De Jager RL, Eckhardt SG, O'Reilly EM. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol. 2006 Sep 20;24(27):4441-7. link to original article contains protocol PubMed
NCIC CTG PA.3: Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W; National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 May 20;25(15):1960-6. Epub 2007 Apr 23. link to original article contains verified protocol PubMed
SAKK 44/00-CECOG/PAN.1.3.001: Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W; Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol. 2007 Jun 1;25(16):2212-7. link to original article contains verified protocol PubMed
1. CBR/QoL analysis: Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi BC, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Herrmann R; Central European Cooperative Oncology Group. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol. 2008 Aug 1;26(22):3695-701. link to original article contains verified protocol PubMed
A4061016: Spano JP, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, Létourneau R, Bajetta E, Pithavala Y, Bycott P, Trask P, Liau K, Ricart AD, Kim S, Rixe O. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet. 2008 Jun 21;371(9630):2101-8. Epub 2008 May 29. link to original article contains verified protocol PubMed
ECOG E6201: Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson AB 3rd. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009 Aug 10;27(23):3778-85. Epub 2009 Jul 6. link to original article contains verified protocol link to PMC article PubMed
Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009 Nov 20;27(33):5513-8. Epub 2009 Oct 26. link to original article contains verified protocol PubMed
GIP-1: Colucci G, Labianca R, Di Costanzo F, Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E, Sannicolò M, Ciaparrone M, Cavanna L, Giuliani F, Maiello E, Testa A, Pederzoli P, Falconi M, Gallo C, Di Maio M, Perrone F; Gruppo Oncologico Italia Meridionale (GOIM); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol. 2010 Apr 1;28(10):1645-51. link to original article contains protocol PubMed
SWOG S0205: Philip PA, Benedetti J, Corless CL, Wong R, O'Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC, Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese JL, Blanke CD. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010 Aug 1;28(22):3605-10. Epub 2010 Jul 6. link to original article contains verified protocol link to PMC article PubMed
CALGB 80303: Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, Picus J, Bhargava P, Mayer RJ, Schilsky RL, Goldberg RM. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010 Aug 1;28(22):3617-22. Epub 2010 Jul 6. link to original article link to PMC article contains protocol PubMed
FFCD 0301: Dahan L, Bonnetain F, Ychou M, Mitry E, Gasmi M, Raoul JL, Cattan S, Phelip JM, Hammel P, Chauffert B, Michel P, Legoux JL, Rougier P, Bedenne L, Seitz JF; Fédération Francophone de Cancérologie Digestive. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut. 2010 Nov;59(11):1527-34. link to original article link to PMC article contains protocol PubMed
A4061028: Kindler HL, Ioka T, Richel DJ, Bennouna J, Létourneau R, Okusaka T, Funakoshi A, Furuse J, Park YS, Ohkawa S, Springett GM, Wasan HS, Trask PC, Bycott P, Ricart AD, Kim S, Van Cutsem E. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 2011 Mar;12(3):256-62. link to original article contains verified protocol PubMed
1. Subgroup analysis: Ioka T, Okusaka T, Ohkawa S, Boku N, Sawaki A, Fujii Y, Kamei Y, Takahashi S, Namazu K, Umeyama Y, Bycott P, Furuse J. Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized phase III trial. Jpn J Clin Oncol. 2015 May;45(5):439-48. Epub 2015 Feb 3. link to original article link to PMC article PubMed
PRODIGE 4/ACCORD 11: Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May 12;364(19):1817-25. link to original article contains verified protocol PubMed
1. QoL analysis: Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Boige V, Bérille J, Conroy T. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol. 2013 Jan 1;31(1):23-9. Epub 2012 Dec 3. link to original article PubMed
BAYPAN: Gonçalves A, Gilabert M, François E, Dahan L, Perrier H, Lamy R, Re D, Largillier R, Gasmi M, Tchiknavorian X, Esterni B, Genre D, Moureau-Zabotto L, Giovannini M, Seitz JF, Delpero JR, Turrini O, Viens P, Raoul JL. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol. 2012 Nov;23(11):2799-805. Epub 2012 Jul 5. link to original article contains protocol PubMed
GEST: Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013 May 1;31(13):1640-8. Epub 2013 Apr 1. link to original article contains verified protocol PubMed
Rougier P, Riess H, Manges R, Karasek P, Humblet Y, Barone C, Santoro A, Assadourian S, Hatteville L, Philip PA. Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur J Cancer. 2013 Aug;49(12):2633-42. Epub 2013 Apr 30. link to original article contains protocol PubMed
MPACT: Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691-703. Epub 2013 Oct 16. link to original article contains verified protocol link to PMC article PubMed
1. Update: Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J, Teixeira L, Tortora G, Van Laethem JL, Young R, Penenberg DN, Lu B, Romano A, Von Hoff DD. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015 Jan 31;107(2). link to original article PubMed
Hong JY, Nam EM, Lee J, Park JO, Lee SC, Song SY, Choi SH, Heo JS, Park SH, Lim HY, Kang WK, Park YS. Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients. Cancer Chemother Pharmacol. 2014 Jan;73(1):125-30. Epub 2013 Oct 27. link to original article contains verified protocol PubMed
GAMMA: Fuchs CS, Azevedo S, Okusaka T, Van Laethem JL, Lipton LR, Riess H, Szczylik C, Moore MJ, Peeters M, Bodoky G, Ikeda M, Melichar B, Nemecek R, Ohkawa S, Świeboda-Sadlej A, Tjulandin SA, Van Cutsem E, Loberg R, Haddad V, Gansert JL, Bach BA, Carrato A. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. Ann Oncol. 2015 May;26(5):921-7. Epub 2015 Jan 21. contains verified protocol link to PMC article PubMed
AB07012: Deplanque G, Demarchi M, Hebbar M, Flynn P, Melichar B, Atkins J, Nowara E, Moyé L, Piquemal D, Ritter D, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Hammel P. A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer. Ann Oncol. 2015 Jun;26(6):1194-200. Epub 2015 Apr 9. link to original article link to PMC article PubMed
O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Leichman L, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler AL, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Ann Oncol. 2015 Sep;26(9):1923-9. Epub 2015 Jun 19. Erratum in: Ann Oncol. 2015 Dec;26(12):2505. Leichman, L [added]. Ann Oncol. 2016 Jun;27(6):1180. link to original article link to PMC article contains protocol PubMed
Catenacci DV, Junttila MR, Karrison T, Bahary N, Horiba MN, Nattam SR, Marsh R, Wallace J, Kozloff M, Rajdev L, Cohen D, Wade J, Sleckman B, Lenz HJ, Stiff P, Kumar P, Xu P, Henderson L, Takebe N, Salgia R, Wang X, Stadler WM, de Sauvage FJ, Kindler HL. Randomized phase Ib/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer. J Clin Oncol. 2015 Dec 20;33(36):4284-92. Epub 2015 Nov 2. link to original article contains protocol in supplement link to PMC article PubMed
Lee HS, Chung MJ, Park JY, Bang S, Park SW, Kim HG, Noh MH, Lee SH, Kim YT, Kim HJ, Kim CD, Lee DK, Cho KB, Cho CM, Moon JH, Kim DU, Kang DH, Cheon YK, Choi HS, Kim TH, Kim JK, Moon J, Shin HJ, Song SY; Korean Society of Gastrointestinal Cancer. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea. Medicine (Baltimore). 2017 Jan;96(1):e5702. contains verified protocol link to PMC article PubMed
ViP: Middleton G, Palmer DH, Greenhalf W, Ghaneh P, Jackson R, Cox T, Evans A, Shaw VE, Wadsley J, Valle JW, Propper D, Wasan H, Falk S, Cunningham D, Coxon F, Ross P, Madhusudan S, Wadd N, Corrie P, Hickish T, Costello E, Campbell F, Rawcliffe C, Neoptolemos JP. Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. Lancet Oncol. 2017 Apr;18(4):486-499. Epub 2017 Mar 2. link to original article contains protocol PubMed

GemOx

back to top

GemOx: Gemcitabine & Oxaliplatin

Regimen

Study	Evidence	Comparator	Efficacy
Louvet et al. 2005	Phase III (E)	Gemcitabine	Seems to have superior PFS
Poplin et al. 2009 (ECOG E6201)	Phase III (E)	1. Gemcitabine	Seems not superior
Poplin et al. 2009 (ECOG E6201)	Phase III (E)	2. Gemcitabine, FDR	Not reported

Chemotherapy

Gemcitabine (Gemzar) 1000 mg/m² IV over 100 minutes once on day 1
Oxaliplatin (Eloxatin) 100 mg/m² IV over 2 hours once on day 2

14-day cycles

References

Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, André T, Zaniboni A, Ducreux M, Aitini E, Taïeb J, Faroux R, Lepere C, de Gramont A; GERCOR; GISCAD. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005 May 20;23(15):3509-16. link to original article contains verified protocol PubMed
ECOG E6201: Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson AB 3rd. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009 Aug 10;27(23):3778-85. Epub 2009 Jul 6. link to original article contains verified protocol link to PMC article PubMed

Gemcitabine & nab-Paclitaxel

back to top

NG: Nab-Paclitaxel & Gemcitabine

Variant #1, with 8-week lead-in

Study	Evidence	Comparator	Efficacy
Von Hoff et al. 2013 (MPACT)	Phase III (E)	Gemcitabine	Superior OS

Chemotherapy

Gemcitabine (Gemzar) as follows, given second:
- Cycle 1: 1000 mg/m² IV once per day on days 1, 8, 15, 29, 36, 43
- Cycle 2 onwards: 1000 mg/m² IV once per day on days 1, 8, 15
Paclitaxel, nanoparticle albumin-bound (Abraxane) as follows, given first:
- Cycle 1: 125 mg/m² IV over 30 to 40 minutes once per day on days 1, 8, 15, 29, 36, 43
- Cycle 2 onwards: 125 mg/m² IV over 30 to 40 minutes once per day on days 1, 8, 15

8-week cycle followed by 28-day cycles

Variant #2, no lead-in

Study	Evidence
Von Hoff et al. 2011	Phase II

Note: The abstract and body of Von Hoff et al. 2011 contradicted each other about which drug is given first in this regimen.

Chemotherapy

Gemcitabine (Gemzar) 1000 mg/m² IV once per day on days 1, 8, 15
Paclitaxel, nanoparticle albumin-bound (Abraxane) 100 or 125 mg/m² IV once per day on days 1, 8, 15

28-day cycles

References

Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011 Dec 1;29(34):4548-54. Epub 2011 Oct 3. link to original article contains verified protocol link to PMC article PubMed
MPACT: Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct 31;369(18):1691-703. Epub 2013 Oct 16. link to original article contains verified protocol link to PMC article PubMed
1. Update: Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J, Teixeira L, Tortora G, Van Laethem JL, Young R, Penenberg DN, Lu B, Romano A, Von Hoff DD. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J Natl Cancer Inst. 2015 Jan 31;107(2). link to original article PubMed

GTX

back to top

GTX: Gemcitabine, Taxotere (Docetaxel), Xeloda (Capecitabine)

Regimen

Study	Evidence
Fine et al. 2007	Retrospective

Note: De Jesus-Acosta et al. 2012 lists the capecitabine dose as "750 mg/m²/day orally divided into two doses," but this is believed to be a typographical error since the original reference that it cites, Fine et al. 2007, uses capecitabine at 750 mg/m² PO twice per day. The 2009 ASCO abstract by Fine also lists this 750 mg/m² PO twice per day (1500 mg/m²/day) dose.

Chemotherapy

Gemcitabine (Gemzar) 750 mg/m² IV over 75 minutes once per day on days 4 & 11
Docetaxel (Taxotere) 30 mg/m² IV once per day on days 4 & 11
Capecitabine (Xeloda) 750 mg/m² PO twice per day on days 1 to 14

21-day cycles

References

Retrospective: Fine RL, Fogelman DR, Schreibman SM, Desai M, Sherman W, Strauss J, Guba S, Andrade R, Chabot J. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis. Cancer Chemother Pharmacol. 2008 Jan;61(1):167-75. Epub 2007 Apr 18. link to original article contains protocol PubMed
Abstract: R. L. Fine, G. Moorer, W. Sherman, K. Chu, M. Maurer, J. Chabot, I. Postolov, J. Prowda, S. Schreibman, J. Levitz. Phase II trial of GTX chemotherapy in metastatic pancreatic cancer. 2009 ASCO Annual Meeting abstract 4623. link to abstract content property of HemOnc.org
Retrospective: De Jesus-Acosta A, Oliver GR, Blackford A, Kinsman K, Flores EI, Wilfong LS, Zheng L, Donehower RC, Cosgrove D, Laheru D, Le DT, Chung K, Diaz LA Jr. A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2012 Feb;69(2):415-24. Epub 2011 Jul 29. link to original article contains verified protocol--with error as noted above link to PMC article PubMed

S-1 monotherapy

back to top

Regimen

Study	Evidence	Comparator	Efficacy
Ueno et al. 2013 (GEST)	Phase III (E)	1. Gemcitabine	Non-inferior OS
Ueno et al. 2013 (GEST)	Phase III (E)	2. Gemcitabine & S-1	Not reported

Chemotherapy

Tegafur, gimeracil, oteracil (S-1) as follows:
- BSA less than 1.25 m²: 40 mg PO twice per day on days 1 to 28
- BSA at least 1.25 m² and less than 1.5 m²: 50 mg PO twice per day on days 1 to 28
- BSA 1.5 m² or more: 60 mg PO twice per day on days 1 to 28

42-day cycles

References

GEST: Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, Shimamura T, Sho M, Kitano M, Cheng AL, Mizumoto K, Chen JS, Furuse J, Funakoshi A, Hatori T, Yamaguchi T, Egawa S, Sato A, Ohashi Y, Okusaka T, Tanaka M. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013 May 1;31(13):1640-8. Epub 2013 Apr 1. link to original article contains verified protocol PubMed

Metastatic disease, refractory

Best supportive care

back to top

Regimen

Study	Evidence	Comparator	Efficacy
Ciuleanu et al. 2009	Phase III (C)	Glufosfamide	Seems not superior
Pelzer et al. 2011	Phase III (C)	OFF	Inferior OS

Best supportive care. Placed here because one or more randomized clinical trials included a best supportive care arm in this disease context.

References

Ciuleanu TE, Pavlovsky AV, Bodoky G, Garin AM, Langmuir VK, Kroll S, Tidmarsh GT. A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur J Cancer. 2009 Jun;45(9):1589-96. Epub 2009 Jan 31. link to original article PubMed
Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, Riess H, Oettle H. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011 Jul;47(11):1676-81. Epub 2011 May 10. link to original article contains verified protocol--with error as noted above PubMed

Capecitabine monotherapy

back to top

Regimen

Study	Evidence	Comparator	Efficacy
Hurwitz et al. 2018 (JANUS 1)	Phase III (C)	Capecitabine & Ruxolitinib	Seems not superior

Chemotherapy

Capecitabine (Xeloda) 1000 mg/m² PO twice per day on days 1 to 14

21-day cycles

References

JANUS 1: Hurwitz H, Van Cutsem E, Bendell J, Hidalgo M, Li CP, Salvo MG, Macarulla T, Sahai V, Sama A, Greeno E, Yu KH, Verslype C, Dawkins F, Walker C, Clark J, O'Reilly EM. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies. Invest New Drugs. 2018 Aug;36(4):683-695. Epub 2018 Mar 6. link to original article contains protocol PubMed

Capecitabine & Erlotinib

back to top

Regimen

Study	Evidence
Kulke et al. 2007	Phase II

Chemotherapy

Capecitabine (Xeloda) 1000 mg/m² (rounded to the nearest 150 mg tablet) PO twice per day on days 1 to 14
Erlotinib (Tarceva) 150 mg PO on days 1 to 21

21-day cycles

References

Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, Fuchs CS. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol. 2007 Oct 20;25(30):4787-92. link to original article contains verified protocol PubMed

CapeOx

back to top

CapeOX: Capecitabine, OXaliplatin
XELOX: XELoda (Capecitabine), OXaliplatin

Regimen

Study	Evidence
Xiong et al. 2008	Phase II

Chemotherapy

Capecitabine (Xeloda) as follows:
- Age less than 65 years old and ECOG performance status less than 2: 1000 mg/m² PO twice per day on days 1 to 14
- Age greater than 65 years old and/or ECOG performance status greater than or equal to 2: 750 mg/m² PO twice per day on days 1 to 14
Oxaliplatin (Eloxatin) as follows:
- Age less than 65 years old and ECOG performance status less than 2: 130 mg/m² IV over 2 hours once on day 1
- Age greater than 65 years old and/or ECOG performance status greater than or equal to 2: 110 mg/m² IV over 2 hours once on day 1

21-day cycles

References

Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer. 2008 Oct 15;113(8):2046-52. link to original article contains verified protocol PubMed

Fluorouracil & Folinic acid

back to top

FF: Fluorouracil & Folinic acid

Variant #1, 2000/200

Study	Evidence	Comparator	Efficacy
Oettle et al. 2014 (CONKO-003)	Phase III (C)	OFF	Inferior OS
Wang-Gillam et al. 2015 (NAPOLI-01)	Phase III (E)	1. Fluorouracil, Folinic acid, nanoliposomal Irinotecan	Seems to have inferior OS
Wang-Gillam et al. 2015 (NAPOLI-01)	Phase III (E)	2. Irinotecan, nanoliposomal	Not reported

Chemotherapy

Fluorouracil (5-FU) 2000 mg/m² IV continuous infusion over 24 hours, started on days 1, 8, 15, 22, given second (total dose per cycle: 8000 mg/m²)
Folinic acid (Leucovorin) 200 mg/m² IV once per day on days 1, 8, 15, 22, given first

42-day cycles

Variant #2, 2800/400

Study	Evidence	Comparator	Efficacy
Gill et al. 2016 (PANCREOX)	Phase III (C)	mFOLFOX6	Seems not superior

Chemotherapy

Fluorouracil (5-FU) 400 mg/m² IV bolus once on day 1, then 2400 mg/m² continuous infusion over 46 hours, given second (total dose per cycle: 2800 mg/m²)
Folinic acid (Leucovorin) 400 mg/m² IV over 2 hours once on day 1, given first

14-day cycles

References

CONKO-003: Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, Görner M, Mölle M, Greten TF, Lakner V, Bischoff S, Sinn M, Dörken B, Pelzer U. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014 Aug 10;32(23):2423-9. Epub 2014 Jun 30. link to original article contains verified protocol PubMed
NAPOLI-1: Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016 Feb 6;387(10018):545-57. Epub 2015 Nov 29. Erratum in: Lancet. 2016 Feb 6;387(10018):536. link to original article contains verified protocol PubMed
PANCREOX: Gill S, Ko YJ, Cripps C, Beaudoin A, Dhesy-Thind S, Zulfiqar M, Zalewski P, Do T, Cano P, Lam WYH, Dowden S, Grassin H, Stewart J, Moore M. PANCREOX: a randomized phase III study of fluorouracil/leucovorin with or without oxaliplatin for second-line advanced pancreatic cancer in patients who have received gemcitabine-based chemotherapy. J Clin Oncol. 2016 Nov 10;34(32):3914-3920. Epub 2016 Sep 30. link to original article contains verified protocol PubMed

Fluorouracil, Folinic acid, nanoliposomal Irinotecan

back to top

Regimen

Study	Evidence	Comparator	Efficacy
Wang-Gillam et al. 2015 (NAPOLI-01)	Phase III (E)	1. Fluorouracil & Folinic acid	Seems to have superior OS
Wang-Gillam et al. 2015 (NAPOLI-01)	Phase III (E)	2. Irinotecan, nanoliposomal	Not reported

Chemotherapy

Fluorouracil (5-FU) 2400 mg/m² IV continuous infusion over 46 hours, started on day 1, given third
Folinic acid (Leucovorin) 400 mg/m² IV over 30 minutes once on day 1, given second
Irinotecan liposome (Onivyde) 70 mg/m² (irinotecan free base) IV over 90 minutes once on day 1, given first
- Per Wang-Gillam et al. 2015 (NAPOLI-01), 70 mg/m² irinotecan free base is equivalent to 80 mg/m² nanoliposomal irinotecan. According to the trial's ClinicalTrials.gov page: "The published dose of ONIVYDE was expressed as the irinotecan hydrochloride trihydrate until October 2015. It is now expressed as the irinotecan free base. Converting a dose based on irinotecan hydrochloride trihydrate to a dose based on irinotecan free base is accomplished by substituting the Molecular Weight of irinotecan hydrochloride trihydrate (677.19 g/mole) with the Molecular Weight of irinotecan free base (586.68 g/mole), which results in a conversion factor of 0.866. 80 mg/m² dose of irinotecan hydrochloride trihydrate is equivalent to 70 mg/m² of irinotecan free base."

14-day cycles

References

NAPOLI-1: Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, Macarulla T, Lee KH, Cunningham D, Blanc JF, Hubner RA, Chiu CF, Schwartsmann G, Siveke JT, Braiteh F, Moyo V, Belanger B, Dhindsa N, Bayever E, Von Hoff DD, Chen LT; NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016 Feb 6;387(10018):545-57. Epub 2015 Nov 29. Erratum in: Lancet. 2016 Feb 6;387(10018):536. link to original article contains verified protocol PubMed

FOLFIRI

back to top

FOLFIRI: FOLinic acid, Fluorouracil, IRInotecan

Variant #1

Study	Evidence
Zaniboni et al. 2012	Phase II

Chemotherapy

Folinic acid (Leucovorin) 200 mg/m² IV once per day on days 1 & 2
Fluorouracil (5-FU) 400 mg/m² IV bolus once per day on days 1 & 2, then 600 mg/m² IV continuous infusion over 22 hours on days 1 & 2 (total dose per cycle: 2000 mg/m²)
Irinotecan (Camptosar) 180 mg/m² IV once on day 1

14-day cycles

Variant #2, modified FOLFIRI.3

Study	Evidence	Comparator	Efficacy
Yoo et al. 2009	Randomized Phase II (E)	mFOLFOX	Seems not superior

Chemotherapy

Folinic acid (Leucovorin) 400 mg/m² IV once on day 1
Fluorouracil (5-FU) 2000 mg/m² IV once per day on days 1 & 2
Irinotecan (Camptosar) 70 mg/m² IV once per day on days 1 & 3

14-day cycles

References

Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, Lee SS, Seo DW, Lee SK, Kim MH, Han DJ, Kim SC, Lee JL. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer. 2009 Nov 17;101(10):1658-63. Epub 2009 Oct 13. link to original article contains protocol link to PMC article PubMed
Zaniboni A, Aitini E, Barni S, Ferrari D, Cascinu S, Catalano V, Valmadre G, Ferrara D, Veltri E, Codignola C, Labianca R. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemother Pharmacol. 2012 Jun;69(6):1641-5. Epub 2012 May 11. link to original article contains protocol PubMed

FOLFOX

back to top

FOLFOX: FOLinic acid, Fluorouracil, OXaliplatin

Regimen

Study	Evidence	Comparator	Efficacy
Yoo et al. 2009	Randomized Phase II (E)	mFOLFIRI.3	Seems not superior

Chemotherapy

Folinic acid (Leucovorin) 400 mg/m² IV once on day 1
Fluorouracil (5-FU) 2000 mg/m² IV once per day on days 1 & 2
Oxaliplatin (Eloxatin) 85 mg/m² IV once on day 1

14-day cycles

References

Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, Lee SS, Seo DW, Lee SK, Kim MH, Han DJ, Kim SC, Lee JL. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer. 2009 Nov 17;101(10):1658-63. Epub 2009 Oct 13. link to original article contains protocol link to PMC article PubMed

Irinotecan liposomal monotherapy

back to top

Regimen

Study	Evidence
Ko et al. 2013 (PEP0208)	Phase II

Chemotherapy

Irinotecan liposome (Onivyde) 120 mg/m² IV once on day 1

21-day cycles

References

PEP0208: Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh CG, Chen LT. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer. 2013 Aug 20;109(4):920-5. link to original article link to PMC article contains protocol PubMed

OLF

back to top

OLF: Oxaliplatin, Leucovorin (Folinic acid), Fluorouracil
OFF: Oxaliplatin, Fluorouracil, Folinic acid

Regimen

Study	Evidence	Comparator	Efficacy
Pelzer et al. 2011	Phase III (E)	Best supportive care	Superior OS
Oettle et al. 2014 (CONKO-003)	Phase III (E)	Fluorouracil & Folinic acid	Superior OS

Note: The treatment section of Pelzer et al. 2011 incorrectly lists the oxaliplatin dose as "0.85 g/m²," or 850 mg/m².

Chemotherapy

Oxaliplatin (Eloxatin) 85 mg/m² IV over 2 to 4 hours once per day on days 8 & 22, given first
Folinic acid (Leucovorin) 200 mg/m² IV bolus once per day on days 1, 8, 15, 22, given second
Fluorouracil (5-FU) 2000 mg/m² IV continuous infusion over 24 hours, started on days 1, 8, 15, 22, given third (total dose per cycle: 8000 mg/m²)

42-day cycles

References

Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, Dörken B, Riess H, Oettle H. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011 Jul;47(11):1676-81. Epub 2011 May 10. link to original article contains verified protocol--with error as noted above PubMed
CONKO-003: Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, Görner M, Mölle M, Greten TF, Lakner V, Bischoff S, Sinn M, Dörken B, Pelzer U. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial. J Clin Oncol. 2014 Aug 10;32(23):2423-9. Epub 2014 Jun 30. link to original article contains verified protocol PubMed

Olaparib monotherapy

back to top

Regimen

Study	Evidence
Kaufman et al. 2014	Phase II

Patients had germline BRCA1/2 mutations.

Preceding treatment

Gemcitabine, with progression

Chemotherapy

Olaparib (Lynparza) 400 mg PO twice per day

Continued indefinitely

References

Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015 Jan 20;33(3):244-50. Epub 2014 Nov 3. link to original article contains verified protocol PubMed

Paclitaxel, nanoparticle albumin-bound monotherapy

back to top

Regimen

Study	Evidence
Hosein et al. 2013	Phase II

Chemotherapy

Paclitaxel, nanoparticle albumin-bound (Abraxane) 100 mg/m² IV over 30 minutes once per day on days 1, 8, 15

28-day cycles

References

Hosein PJ, de Lima Lopes G Jr, Pastorini VH, Gomez C, Macintyre J, Zayas G, Reis I, Montero AJ, Merchan JR, Rocha Lima CM. A phase II trial of nab-paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Am J Clin Oncol. 2013 Apr;36(2):151-6. Epub 2012 Feb 2. link to original article contains protocol PubMed

@@ Line 40: / Line 40: @@
 ===Regimen {{#subobject:e6a3e3|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32409-6/fulltext Neoptolemos et al. 2017 (ESPAC-4)]
@@ Line 70: / Line 70: @@
 ===Regimen {{#subobject:242770|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 | rowspan="2" |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(01)06651-X/fulltext Neoptolemos et al. 2001 (ESPAC-1)]
@@ Line 117: / Line 117: @@
 ===Regimen {{#subobject:89426a|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 | rowspan="2" |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(01)06651-X/fulltext Neoptolemos et al. 2001 (ESPAC-1)]
@@ Line 169: / Line 169: @@
 ===Regimen {{#subobject:a170cb|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
+! style="width: 20%" |Study
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
+! style="width: 20%" |Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 20%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
-!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
+! style="width: 20%" |[[Levels_of_Evidence#Toxicity|Toxicity]]
 |-
 |[https://www.nejm.org/doi/full/10.1056/NEJMoa1809775 Conroy et al. 2018 (NCIC CTG PA.6)]
@@ Line 202: / Line 202: @@
 ===Variant #1, 2 out of 3 weeks {{#subobject:dc12dc|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 50%"|Study
+! style="width: 50%" |Study
-!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403240/ Landry et al. 2010]
@@ Line 218: / Line 218: @@
 ===Variant #2, 3 out of 4 weeks {{#subobject:a756a2|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[http://jama.ama-assn.org/content/297/3/267.long Oettle et al. 2007 (CONKO-001)]
@@ Line 288: / Line 288: @@
 ===Regimen {{#subobject:3fef3f|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[http://jama.ama-assn.org/content/299/9/1019.long Regine et al. 2008 (RTOG 9704)]
@@ Line 330: / Line 330: @@
 ===Regimen===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1420941/ Klinkenbijl et al. 1999 (EORTC 40891)]
@@ Line 372: / Line 372: @@
 ===Regimen {{#subobject:cdcc15|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)30583-9/fulltext Uesaka et al. 2016 (JASPAC 01)]
@@ Line 407: / Line 407: @@
 ===Regimen {{#subobject:78b0ba|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 50%"|Study
+! style="width: 50%" |Study
-!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[http://link.springer.com/article/10.1245%2FASO.2005.04.503 Pipas et al. 2005]
@@ Line 442: / Line 442: @@
 ===Variant #1 {{#subobject:6ce551|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 50%"|Study
+! style="width: 50%" |Study
-!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[http://journals.lww.com/annalsofsurgery/pages/articleviewer.aspx?year=2013&issue=12000&article=00029&type=abstract Takahashi et al. 2013]
@@ Line 460: / Line 460: @@
 ===Variant #2 {{#subobject:dc32dc|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 50%"|Study
+! style="width: 50%" |Study
-!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403240/ Landry et al. 2010]
@@ Line 487: / Line 487: @@
 ===Regimen {{#subobject:c38534|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 50%"|Study
+! style="width: 50%" |Study
-!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577039/ Pipas et al. 2012]
@@ Line 511: / Line 511: @@
 ===References===
 # Pipas JM, Zaki BI, McGowan MM, Tsapakos MJ, Ripple GH, Suriawinata AA, Tsongalis GJ, Colacchio TA, Gordon SR, Sutton JE, Srivastava A, Smith KD, Gardner TB, Korc M, Davis TH, Preis M, Tarczewski SM, Mackenzie TA, Barth RJ Jr. Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma. Ann Oncol. 2012 Nov;23(11):2820-7. Epub 2012 May 9. [http://annonc.oxfordjournals.org/content/23/11/2820.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577039/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22571859 PubMed]
+== FOLFIRINOX/modified FOLFIRINOX +/- Chemoradiation ==
+{| class="wikitable" style="width: 100%; text-align:center;"
+! style="width: 50%" |Study
+! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
+|-
+|Murphy et al. 2018
+| style="background-color:#91cf61" |Phase II
+|-
+|}
+''Note: FOLFIRINOX should be limited to those with ECOG 0-1''
+==== Chemotherapy ====
+* Folinic acid (Leucovorin) 400 mg/m<sup>2</sup> IV over 2 hours once on day 1, given second
+* Fluorouracil (5-FU) 400 mg/m<sup>2</sup> IV bolus once on day 1, then 2400 mg/m<sup>2</sup> IV continuous infusion over 46 hours, given fourth (total dose per cycle: 2800 mg/m<sup>2</sup>)
+* Irinotecan (Camptosar) 180* mg/m<sup>2</sup> IV over 90 minutes once on day 1, given third with the last 90 minutes of leucovorin; that is, irinotecan starts 30 minutes after the start of leucovorin
+* Oxaliplatin (Eloxatin) 85 mg/m<sup>2</sup> IV over 2 hours once on day 1, given first
+==== Supportive medications ====
+* Pegfilgrastim (Neulasta) 6 mg SC once on day 4
+'''14-day cycle for 8* cycles'''
+<nowiki>*</nowiki>Amendment after first 6 patients were enrolled increased neoadjuvant cycles from 4 to 8 if no progression was detected on restaging CT
+Followed by restaging with CT scan. If tumor was resectable (no vascular involvement), they received short-course proton chemoradiotherapy:
+==== Proton Chemoradiotherapy ====
+* Capecitabine 825 mg/m<sup>2</sup> PO BID, Monday – Friday for 2 weeks
+* Proton radiotherapy of 25 GyE in 5 treatments OR Intensity modulated radiotherapy (IMRT) of 30 Gy in 10 fractions
+=== References ===
+# Murphy J.E., Wo J.Y., Ryan D.P., Jiang W., Yeap B.Y., Drapek L.C., Blaszkowsky L.S., Kwak E.L., Allen J.N., Clark J.W., et al. Total neoadjuvant therapy with folfirinox followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: A phase 2 clinical trial. JAMA Oncol. 2018; 4:963–969. doi: 10.1001/jamaoncol.2018.0329. Link to original article: <nowiki>https://jamanetwork.com/journals/jamaoncology/fullarticle/2679565</nowiki> contains verified protocol Pubmed: https://www.ncbi.nlm.nih.gov/pubmed/29800971
 ==mFOLFIRINOX, Gemcitabine, RT {{#subobject:b71003|Regimen=1}}==
@@ Line 520: / Line 552: @@
 ===Variant #1 {{#subobject:d87ec0|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 50%"|Study
+! style="width: 50%" |Study
-!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4373613/ Blazer et al. 2015]
@@ Line 547: / Line 579: @@
 ===Variant #2 {{#subobject:7bb0e7|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 50%"|Study
+! style="width: 50%" |Study
-!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404979/ Hosein et al. 2012]
@@ Line 582: / Line 614: @@
 ===Regimen {{#subobject:dc4779|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 50%"|Study
+! style="width: 50%" |Study
-!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[http://jco.ascopubs.org/content/20/1/160.long Cartwright et al. 2002]
@@ Line 604: / Line 636: @@
 ===Variant #1, Gem 3 out of 4 weeks x 4 {{#subobject:87edde|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2016.4324 Hammel et al. 2016 (GERCOR LAP07)]
@@ Line 625: / Line 657: @@
 ===Variant #2, Gem 3 out of 4 weeks x 6 {{#subobject:5a5e14|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2016.4324 Hammel et al. 2016 (GERCOR LAP07)]
@@ Line 651: / Line 683: @@
 |}
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[http://jco.ascopubs.org/content/25/15/1960.long Moore et al. 2007 (NCIC CTG PA.3)]
@@ Line 672: / Line 704: @@
 ===Variant #4, gemcitabine lead-in, erlotinib 150 mg/day {{#subobject:b7a41f|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[http://jco.ascopubs.org/content/25/15/1960.long Moore et al. 2007 (NCIC CTG PA.3)]
@@ Line 704: / Line 736: @@
 ===Regimen {{#subobject:29784e|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19811015)48:8%3C1705::AID-CNCR2820480803%3E3.0.CO;2-4 Moertel et al. 1981]
@@ Line 739: / Line 771: @@
 ===Variant #1, 3 out of 4 weeks x 4 {{#subobject:c511a7|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2016.4324 Hammel et al. 2016 (GERCOR LAP07)]
@@ Line 759: / Line 791: @@
 ===Variant #2, 3 out of 4 weeks x 6 {{#subobject:cf89f2|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2016.4324 Hammel et al. 2016 (GERCOR LAP07)]
@@ Line 777: / Line 809: @@
 ===Variant #3, 8-week lead-in ("Burris regimen") {{#subobject:82f8b2|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://www.tandfonline.com/doi/abs/10.1179/joc.2004.16.6.589 Cantore et al. 2004]
@@ Line 827: / Line 859: @@
 ===Variant #1 (600 mg/m<sup>2</sup>) {{#subobject:a6de29|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[http://journals.lww.com/amjclinicaloncology/pages/articleviewer.aspx?year=2011&issue=10000&article=00004&type=abstract Cardenes et al. 2011]
@@ Line 856: / Line 888: @@
 ===Variant #2 (400 mg/m<sup>2</sup>) {{#subobject:c1ac3c|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 50%"|Study
+! style="width: 50%" |Study
-!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[https://onlinelibrary.wiley.com/doi/10.1002/jso.10159/abstract Epelbaum et al. 2002]
@@ Line 892: / Line 924: @@
 ===Regimen {{#subobject:5a25e9|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[http://jco.ascopubs.org/content/23/15/3509.long Louvet et al. 2005]
@@ Line 922: / Line 954: @@
 ===Regimen {{#subobject:ce3d2d|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://www.redjournal.org/article/S0360-3016(05)00096-9/fulltext Cohen et al. 2005 (ECOG E8282)]
@@ Line 948: / Line 980: @@
 ===Regimen {{#subobject:b31bbb|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 50%"|Study
+! style="width: 50%" |Study
-!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[http://jco.ascopubs.org/content/20/1/160.long Cartwright et al. 2002]
@@ Line 971: / Line 1,003: @@
 ===Variant #1 {{#subobject:fcd708|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228666/ Lee et al. 2017]
@@ Line 991: / Line 1,023: @@
 ===Variant #2 {{#subobject:e8f0bf|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[http://jco.ascopubs.org/content/27/33/5513.long Cunningham et al. 2009]
@@ Line 1,016: / Line 1,048: @@
 ===Variant #3 {{#subobject:a7e551|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[http://jco.ascopubs.org/content/25/16/2212.long Herrmann et al. 2007 (SAKK 44/00-CECOG/PAN.1.3.001)]
@@ Line 1,046: / Line 1,078: @@
 ===Variant #1, 25/1000, weekly dosing {{#subobject:20a0f9|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.10323 Colucci et al. 2002]
@@ Line 1,075: / Line 1,107: @@
 ===Variant #2, 35/1000, 2 out of 3 weeks {{#subobject:38caf7|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(07)70383-2/abstract Cascinu et al. 2008]
@@ Line 1,093: / Line 1,125: @@
 ===Variant #3, 50/1000, bi-weekly dosing {{#subobject:38caf7|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[http://jco.ascopubs.org/content/24/24/3946.long Heinemann et al. 2006]
@@ Line 1,123: / Line 1,155: @@
 ===Variant #1, no gemcitabine lead-in {{#subobject:43fe43|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00027-3/fulltext Kordes et al. 2015]
@@ Line 1,146: / Line 1,178: @@
 |}
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[http://jco.ascopubs.org/content/25/15/1960.long Moore et al. 2007 (NCIC CTG PA.3)]
@@ Line 1,172: / Line 1,204: @@
 ===Variant #3, gemcitabine lead-in, erlotinib 150 mg/day {{#subobject:d49fb0|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[http://jco.ascopubs.org/content/25/15/1960.long Moore et al. 2007 (NCIC CTG PA.3)]
@@ Line 1,210: / Line 1,242: @@
 ===Variant #1, 300 mg/m<sup>2</sup>/day PVI {{#subobject:3ac41f|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[http://ascopubs.org/doi/full/10.1200/JCO.2002.09.029 Maisey et al. 2002]
@@ Line 1,228: / Line 1,260: @@
 ===Variant #2, 500 mg/m<sup>2</sup> intermittent {{#subobject:27a992|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://jamanetwork.com/journals/jama/fullarticle/397816 Cullinan et al. 1985]
@@ Line 1,252: / Line 1,284: @@
 ===Variant #2, 600 mg/m<sup>2</sup> weekly {{#subobject:3ca01f|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[http://jco.ascopubs.org/content/15/6/2403.long Burris et al. 1997]
@@ Line 1,283: / Line 1,315: @@
 ===Regimen {{#subobject:e140cb|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
+! style="width: 20%" |Study
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
+! style="width: 20%" |Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 20%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
-!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
+! style="width: 20%" |[[Levels_of_Evidence#Toxicity|Toxicity]]
 |-
 |[https://www.nejm.org/doi/full/10.1056/NEJMoa1011923 Conroy et al. 2011 (PRODIGE 4/ACCORD 11)]
@@ Line 1,315: / Line 1,347: @@
 ===Variant #1, 900 mg/m<sup>2</sup>, 3 out of 4 weeks {{#subobject:c61ab9|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360678/ Stathopoulos et al. 2006]
@@ Line 1,333: / Line 1,365: @@
 ===Variant #2, 1000 mg/m<sup>2</sup>, 8-week lead-in ("Burris regimen") {{#subobject:5d6dd0|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[http://jco.ascopubs.org/content/15/6/2403.long Burris et al. 1997]
@@ Line 1,436: / Line 1,468: @@
 | style="background-color:#d73027" |Inferior OS
 |-
-|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516046/  Deplanque et al. 2015 (AB07012)]
+|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516046/ Deplanque et al. 2015 (AB07012)]
 | style="background-color:#1a9851" |Phase III (C)
 |Gemcitabine & Masitinib
@@ Line 1,458: / Line 1,490: @@
 ===Variant #3, 1000 mg/m<sup>2</sup>, 3 out of 4 weeks {{#subobject:c6349|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[http://ascopubs.org/doi/full/10.1200/JCO.2002.11.149 Berlin et al. 2002 (ECOG E2297)]
@@ Line 1,529: / Line 1,561: @@
 ===Variant #4, 1000 mg/m<sup>2</sup>, weekly {{#subobject:8bae67|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://link.springer.com/article/10.1007%2Fs00280-013-2328-1 Hong et al. 2013]
@@ Line 1,547: / Line 1,579: @@
 ===Variant #5, 1500 mg/m<sup>2</sup>, fixed-dose rate (FDR) {{#subobject:5114cc|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 | rowspan="2" |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727286/ Poplin et al. 2009 (ECOG E6201)]
@@ Line 1,615: / Line 1,647: @@
 ===Regimen {{#subobject:9d3266|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[http://jco.ascopubs.org/content/23/15/3509.long Louvet et al. 2005]
@@ Line 1,652: / Line 1,684: @@
 ===Variant #1, with 8-week lead-in {{#subobject:63ba04|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4631139/ Von Hoff et al. 2013 (MPACT)]
@@ Line 1,675: / Line 1,707: @@
 ===Variant #2, no lead-in {{#subobject:ecc1c9|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 50%"|Study
+! style="width: 50%" |Study
-!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565012/ Von Hoff et al. 2011]
@@ Line 1,704: / Line 1,736: @@
 ===Regimen {{#subobject:fc0e50|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 50%"|Study
+! style="width: 50%" |Study
-!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[http://www.springerlink.com/content/75m422843l3461m0/ Fine et al. 2007]
@@ Line 1,731: / Line 1,763: @@
 ===Regimen {{#subobject:94d490|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 | rowspan="2" |[http://ascopubs.org/doi/full/10.1200/JCO.2012.43.3680 Ueno et al. 2013 (GEST)]
@@ Line 1,766: / Line 1,798: @@
 ===Regimen===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://www.ejcancer.com/article/S0959-8049(08)01051-4/fulltext Ciuleanu et al. 2009]
@@ Line 1,796: / Line 1,828: @@
 ===Regimen {{#subobject:3ab38a|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://link.springer.com/article/10.1007%2Fs10637-018-0580-2 Hurwitz et al. 2018 (JANUS 1)]
@@ Line 1,822: / Line 1,854: @@
 ===Regimen {{#subobject:d5c799|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 50%"|Study
+! style="width: 50%" |Study
-!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[http://jco.ascopubs.org/content/25/30/4787.full Kulke et al. 2007]
@@ Line 1,848: / Line 1,880: @@
 ===Regimen {{#subobject:57ad5f|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 50%"|Study
+! style="width: 50%" |Study
-!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[https://onlinelibrary.wiley.com/doi/10.1002/cncr.23810/full Xiong et al. 2008]
@@ Line 1,876: / Line 1,908: @@
 ===Variant #1, 2000/200 {{#subobject:b631e0|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[http://jco.ascopubs.org/content/32/23/2423.long Oettle et al. 2014 (CONKO-003)]
@@ Line 1,903: / Line 1,935: @@
 ===Variant #2, 2800/400 {{#subobject:959e8e|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[http://ascopubs.org/doi/full/10.1200/JCO.2016.68.5776 Gill et al. 2016 (PANCREOX)]
@@ Line 1,933: / Line 1,965: @@
 ===Regimen {{#subobject:a81310|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 | rowspan="2" |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)00986-1/abstract Wang-Gillam et al. 2015 (NAPOLI-01)]
@@ Line 1,967: / Line 1,999: @@
 ===Variant #1 {{#subobject:6a9cae|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 50%"|Study
+! style="width: 50%" |Study
-!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[http://link.springer.com/article/10.1007%2Fs00280-012-1875-1 Zaniboni et al. 2012]
@@ Line 1,983: / Line 2,015: @@
 ===Variant #2, modified FOLFIRI.3 {{#subobject:4758e8|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778540/ Yoo et al. 2009]
@@ Line 2,013: / Line 2,045: @@
 ===Regimen {{#subobject:33ef68|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778540/ Yoo et al. 2009]
@@ Line 2,041: / Line 2,073: @@
 ===Regimen {{#subobject:c50e15|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 50%"|Study
+! style="width: 50%" |Study
-!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749576/ Ko et al. 2013 (PEP0208)]
@@ Line 2,065: / Line 2,097: @@
 ===Regimen {{#subobject:ae57d5|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+! style="width: 25%" |Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|Comparator
+! style="width: 25%" |Comparator
-!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
+! style="width: 25%" |[[Levels_of_Evidence#Efficacy|Efficacy]]
 |-
 |[https://www.ejcancer.com/article/S0959-8049(11)00260-7/abstract Pelzer et al. 2011]
@@ Line 2,102: / Line 2,134: @@
 ===Regimen {{#subobject:21eb78|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 50%"|Study
+! style="width: 50%" |Study
-!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[http://jco.ascopubs.org/content/33/3/244.long Kaufman et al. 2014]
@@ Line 2,128: / Line 2,160: @@
 ===Regimen {{#subobject:8d38d2|Variant=1}}===
 {| class="wikitable" style="width: 100%; text-align:center;"
-!style="width: 50%"|Study
+! style="width: 50%" |Study
-!style="width: 50%"|[[Levels_of_Evidence#Evidence|Evidence]]
+! style="width: 50%" |[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[https://insights.ovid.com/pubmed?pmid=22307213 Hosein et al. 2013]

Difference between revisions of "Pancreatic cancer"

Revision as of 19:58, 28 March 2019

Guidelines

ASCO

Older

ESMO

NCCN

Adjuvant therapy

Capecitabine & Gemcitabine

Regimen

Preceding treatment

Chemotherapy

References

Fluorouracil & Folinic acid

Regimen

Preceding treatment

Chemotherapy

References

Fluorouracil/Fluorouracil & RT

Regimen

Preceding treatment

Chemotherapy, part 1

Chemoradiotherapy

Chemotherapy, part 2

References

mFOLFIRINOX

Regimen

Preceding treatment

Chemotherapy

References

Gemcitabine monotherapy

Variant #1, 2 out of 3 weeks

Preceding treatment

Chemotherapy

Variant #2, 3 out of 4 weeks

Preceding treatment

Chemotherapy

References

Gemcitabine/Fluorouracil & RT

Regimen

Preceding treatment

Chemotherapy, part 1

Chemoradiotherapy

Chemotherapy, part 2

References

Observation

Regimen

Preceding treatment

References

S-1 monotherapy

Regimen

Preceding treatment

Chemotherapy

References

Induction therapy for locally advanced disease, potentially resectable

Docetaxel, Gemcitabine, RT

Regimen

Chemotherapy

Chemoradiation

Supportive medications

References

Gemcitabine & RT

Variant #1

Chemoradiotherapy

Subsequent treatment

Variant #2

Chemoradiotherapy

Subsequent treatment

References

Gemcitabine, Cetuximab, RT

Regimen

Chemoradiotherapy

Supportive medications

References

FOLFIRINOX/modified FOLFIRINOX +/- Chemoradiation

Chemotherapy

Supportive medications

Proton Chemoradiotherapy

References

mFOLFIRINOX, Gemcitabine, RT

Variant #1 (600 mg/m²)

Variant #2 (400 mg/m²)